

**Wednesday, 04. June 2025**

*Poster Mounting and Dismounting*  
17:00 - 20:00

**Poster Mounting**

*Opening Plenary*  
18:30 - 20:00

**Opening Plenary****Welcome address**

18:30 - 18:30

*Speaker:* Jane Davies (London, United Kingdom)

**Welcome ECFS Conference Patron**

18:30 - 18:30

*Speaker:* Francesco Blasi (Milan, Italy)

**Down the road: navigating the CF streets ahead**

18:30 - 18:30

*Speaker:* Carlo Castellani (Genoa, Italy)

**Presentation of the ECFS Award**

18:30 - 18:30

**ECFS Award Lecture: CFTR modulators in non-F508del people with CF**

18:30 - 18:30

*Speaker:* Pierre-Régis Burgel (Paris, France)

**Presentation of Gerd Döring Award**

18:30 - 18:30

**Presentation of the CFE Advocacy Award**

18:30 - 18:30

**Thursday, 05. June 2025***Meet the Experts*

07:45 - 08:45

**MTE 1 - MTE 1 - Lessons learned from real-world studies - why, how and what?***Expert:* Anna-Maria Ditttrich (Hanover, Germany)*Expert:* Clémence Martin (Paris, France)*Meet the Experts*

07:45 - 08:45

**MTE 2 - MTE 2 - Menopause - Understanding and supporting women***Expert:* Jennifer L. Taylor-Cousar (Denver, United States)*Meet the Experts*

07:45 - 08:45

**MTE 3 - MTE 3 - Lung transplant - indications and management***Expert:* Lieven Dupont (Leuven, Belgium)*Expert:* Peter Barry (Manchester, United Kingdom)*Symposium*

09:00 - 10:30

**S01 - Symposium 01 - The European initiative for (ultra-)rare variants***Moderator:* Margarida Amaral (Lisboa, Portugal)*Moderator:* Pavel Drevinek (Prague, Czech Republic)**The HIT-CF project and CHOICES Trial**

09:00 - 09:22

*Speaker:* Kors Van der Ent (Utrecht, Netherlands)**Regulatory perspectives on licensing for ultrarare variants**

09:22 - 09:44

*Speaker:* Enrico Costa (Rome, Italy)**Expanding the CTN to countries with ultrarare variants - Status quo and future perspectives**

09:44 - 10:06

*Speaker:* Nicholas Simmonds (London, United Kingdom)**Levelling the playing field for patients with cystic fibrosis carrying rare and ultrarare variants**

10:06 - 10:30

*Speaker:* Kris De Boeck (Leuven, Belgium)*Symposium*

09:00 - 10:30

**S02 - Symposium 02 - Unveiling novel therapeutic targets for microbial pathogen control***Moderator:* Jean-Luc Mainardi (Paris, France)*Moderator:* Maria Pals Bendixen (Copenhagen, Denmark)**Pseudopaline in *Pseudomonas aeruginosa* - the role metallophores play during chronic bacterial infection**

09:00 - 09:22

*Speaker:* Romé Voulhoux (Marseille, France)**Disrupting division - virtual screening-derived compound inhibits *Staphylococcus aureus* division**

09:22 - 09:44

*Speaker:* Viola Camilla Scoffone (Pavia, Italy)**Cracking the code - overcoming aminoglycoside resistance in *Mycobacterium abscessus***

09:44 - 10:06

*Speaker:* Peter Sander (Zurich, Switzerland)**Frontiers in lung infection modelling - Air-Liquid-Interface (ALI) systems and microbial dynamics in cystic fibrosis**

10:06 - 10:30

*Speaker:* Helle Krogh Johansen (Copenhagen, Denmark)

## Symposium

09:00 - 10:30

**S03 - Symposium 03 - Is inflammation still relevant in cystic fibrosis?**

Moderator: Stéphanie Bui (Bordeaux, France)

Moderator: Giulio Cabrini (Ferrara, Italy)

**Understanding inflammation in cystic fibrosis through proteomics**

09:00 - 09:22

Speaker: Cliff Taggart (Belfast, United Kingdom)

**The cystic fibrosis lung, a very heterogenous organ?**

09:22 - 09:44

Speaker: Pradeep Singh (Seattle, United States)

**The gut-lung axis**

09:44 - 10:06

Speaker: Raphael Enaud (Bordeaux, France)

**Emerging treatments for lung inflammation in cystic fibrosis**

10:06 - 10:30

Speaker: Michal Shteinberg (Haifa, Israel)

## Symposium

09:00 - 10:30

**S04 - Symposium 04 - When care causes trauma - how to support patients with cystic fibrosis and their families**

Moderator: Sonia Graziano (Rome, Italy)

Moderator: Johanna Gardecki (Frankfurt, Germany)

**When parenthood is not my only responsibility - attachment disturbances caused by cystic fibrosis**

09:00 - 09:22

Speaker: Pavla Hodkova (Prague, Czech Republic)

**Medical trauma and procedural anxiety - prevention and intervention**

09:22 - 09:44

Speaker: Addison Cuneo (San Francisco, United States)

**When values conflict with requirements - cause of distress for both PwCF and professionals**

09:44 - 10:06

Speaker: Helen Love (Nottingham, United Kingdom)

**Did I lose my chance for life? - when PwCF cannot benefit from CFTR modulator therapy**

10:06 - 10:30

Speaker: Sue Braun (Brussels, Belgium)

## Symposium

09:00 - 10:30

**S05 - Symposium 05 - Getting to grips with CFTR genetics to optimise patient care**

Moderator: Halyna Makukh (Lviv, Ukraine)

Moderator: Carlo Castellani (Genoa, Italy)

**Demystifying genetic reports: how do we name and classify CFTR gene variants**

09:00 - 09:22

Speaker: Michael Morris (Munich, Switzerland)

**Understanding and getting the most from the CFTR2 database**

09:22 - 09:44

Speaker: Karen Raraigh (Baltimore, United States)

**Understanding and getting the most from the CFTR-France database**

09:44 - 10:06

Speaker: Emmanuelle Girodon (Paris, France)

**Improving the quality of genetic data in patient registries: barriers and opportunities**

10:06 - 10:30

Speaker: Lutz Naehrlich (Giessen, Germany)

*ECFS Tomorrow Lounge Session*

09:00 - 10:00

**CF Life: more than just popping a pill - challenges for physiotherapy***Moderator:* Brenda Button (Melbourne, Australia)*Moderator:* Lisa Morrison (Glasgow, United Kingdom)*Moderator:* Gemma. E. Stanford (London, United Kingdom)*ECFS Tomorrow Lounge Session*

10:30 - 11:00

**Speaker Corner***Speaker:* Anna-Maria Dittrich (Hanover, Germany)*Speaker:* Kris De Boeck (Leuven, Belgium)*Speaker:* Stéphanie Bui (Bordeaux, France)*Speaker:* Cliff Taggart (Belfast, United Kingdom)*Speaker:* Sonia Graziano (Rome, Italy)*Speaker:* Karen Raraigh (Baltimore, United States)*Coffee Break*

10:30 - 11:00

**Coffee Break***Symposium*

11:00 - 12:30

**S06 - Symposium 06 - Considerations in advanced lung disease***Moderator:* Clémence Martin (Paris, France)*Moderator:* Andrea Gramegna (Milan, Italy)**Is pregnancy now safe in all women with cystic fibrosis**

11:00 - 11:22

*Speaker:* Malena Cohen-Cymberknoh (Jerusalem, Israel)**Red alert! Haemoptysis in cystic fibrosis**

11:22 - 11:44

*Speaker:* Andrew Jones (Manchester, United Kingdom)**Treatment of exacerbations in advanced lung disease, where are we now?**

11:44 - 12:06

*Speaker:* Edward McKone (Dublin, Ireland)**Threshold for intensive care referral, has it changed?**

12:06 - 12:30

*Speaker:* Mark O'Carroll (Auckland, New Zealand)*Symposium*

11:00 - 12:30

**S07 - Symposium 07 - Infection management in cystic fibrosis - beyond *Pseudomonas aeruginosa* and *Staphylococcus aureus****Moderator:* Helle Krogh Johansen (Copenhagen, Denmark)*Moderator:* Nicola Ivan Lorè (Milan, Italy)**Fungal perspectives - aspergillus in the context of ETI treatment**

11:00 - 11:22

*Speaker:* Carsten Schwarz (Potsdam, Germany)**Modulation of bacterial colonisation - the role of mucoid *Staphylococcus aureus* in cystic fibrosis**

11:22 - 11:44

*Speaker:* Barbara Kahl (Münster, Germany)**Navigating microbial surveillance in the ETI era - insights from the BRONCH-CF Study**

11:44 - 12:06

*Speaker:* Gisli Einarsson (Belfast, United Kingdom)**Tackling achromobacter and stenotrophomonas - clinical lab insights**

12:06 - 12:30

*Speaker:* Geneviève Héry-Arnaud (Brest, France)

## Symposium

11:00 - 12:30

**S08 - Symposium 08 - Organ-specific interplay between CFTR and channels/transporters in transepithelial anion transport***Moderator:* László Csanády (Budapest, Hungary)*Moderator:* Vinciane Saint-Criq (Jouy-en-Josas, France)**Novel regulation of CFTR in the respiratory epithelium by luminal succinate signaling**

11:00 - 11:22

*Speaker:* Michael Gray (Newcastle upon Tyne, United Kingdom)**Ion transport in the renal tubule of the kidney**

11:22 - 11:44

*Speaker:* Peder Berg (Aarhus, Denmark)**Ion transport in the intestinal epithelium**

11:44 - 12:06

*Speaker:* Ursula Seidler (Hannover, Germany)**Ion transport in the pancreatic duct**

12:06 - 12:30

*Speaker:* Viktória Venglovecz (Szeged, Hungary)

## Symposium

11:00 - 12:30

**S09 - Symposium 09 - The new faces of pancreas***Moderator:* Stephanie Van Biervliet (Ghent, Belgium)*Moderator:* Marco Cipolli (Verona, Italy)**Prediction, risk factors and prevention of pancreatic disease**

11:00 - 11:22

*Speaker:* Andrea Párniczky (Budapest, Hungary)**The effect of modulators on pancreatic function and CFTR-RD**

11:22 - 11:44

*Speaker:* Michael Wilschanski (Jerusalem, Israel)**New tests for malabsorption and pancreatic function**

11:44 - 12:06

*Speaker:* Steven D. Freedman (Boston, United States)**Advances in PERT and alternative sources**

12:06 - 12:30

*Speaker:* Tanja Gonska (Toronto, Canada)

## Symposium

11:00 - 12:30

**S10 - Symposium 10 - Exercise and physiotherapy throughout the lifespan***Moderator:* Gemma. E. Stanford (London, United Kingdom)*Moderator:* Thomas Radtke (Zurich, Switzerland)**Strong starts - physio and exercise interventions for babies/toddlers with cystic fibrosis and their families**

11:00 - 11:22

*Speaker:* Lue Philipsen (Copenhagen, Denmark)**How (and what) to keep going - exercise and physio interventions throughout the lifespan**

11:22 - 11:44

*Speaker:* Donald Urquhart (Edinburgh, United Kingdom)**Maintaining cystic fibrosis health during pregnancy and parenthood - the role of physiotherapy and exercise**

11:44 - 12:06

*Speaker:* Clare M Reilly (Dublin, Ireland)**The cystic fibrosis athlete - patient perspectives**

12:06 - 12:30

*Speaker:* Stephan Kruip (Zorneding, Germany)

*ECFS Tomorrow Lounge Session*

12:45 - 13:45

**How are we measuring mental health and quality of life impacts of CFTR modulators?***Moderator:* Edwina Landau (Petah Tikva, Israel)*Moderator:* Anna M. Georgiopoulos (Boston, United States)*Moderator:* Helen Love (Nottingham, United Kingdom)*Moderator:* Marieke Verkleij (Amsterdam, Netherlands)*Industry Sessions*

13:00 - 14:00

**Industry Symposium***ePoster Session*

14:00 - 15:00

**EPS 1 - ePoster Session 1 - Improving communication and care within the CFTR Modulator landscape - challenges and chances***Leader:* Paula Lomas (Warminster, United States)*Leader:* Edwina Landau (Petah Tikva, Israel)

EPS1.01	<b>Mental health and parental stress among parents of children with rare genetic disorders and healthy controls</b>	14:00 - 14:06
---------	---	---------------

*Oral ePoster presenter:* Urszula Borawska - Kowalczyk (Warsaw, Poland)

EPS1.02	<b>Enhancing CF nurse coordinator well-being and decrease burnout through small group discussions: a six-month pilot program</b>	14:06 - 14:12
---------	--	---------------

*Oral ePoster presenter:* Paula Lomas (Warminster, United States)

EPS1.03	<b>Is ChatGPT better than the CF care team at answering patient questions?</b>	14:12 - 14:18
---------	--	---------------

*Oral ePoster presenter:* Tamara Vagg (Cork, Ireland)

EPS1.04	<b>Updating practice in the management of pregnancy in cystic fibrosis in the modulator era</b>	14:18 - 14:24
---------	---	---------------

*Oral ePoster presenter:* Hannah Parkinson (London, United Kingdom)

EPS1.05	<b>Sleep quality and mental health in children with cystic fibrosis: the impact of elexacaftor/tezacaftor/ivacaftor therapy</b>	14:24 - 14:30
---------	---	---------------

*Oral ePoster presenter:* Beste Ozsezen (Izmir, Turkey)

EPS1.06	<b>Adherence to elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis</b>	14:30 - 14:36
---------	---	---------------

*Oral ePoster presenter:* Ulrika Skogeland (Stockholm, Sweden)

EPS1.07	<b>Tears, tantrums and terrors: sleep disturbance and behavioural side effects in children aged 2-5 years with cystic fibrosis commencing triple CFTR modulator therapy, and a pathway for their management</b>	14:36 - 14:42
---------	---	---------------

*Oral ePoster presenter:* Kathryn Kimber (Cambridge, United Kingdom)

EPS1.08	<b>Overview of circadian rhythm disorders in children with cystic fibrosis in the era of CFTR (cystic fibrosis transmembrane conductance regulator) modulators (CHRONO-MUCO)</b>	14:42 - 14:48
---------	--	---------------

*Oral ePoster presenter:* Catherine CHEN (Bron, France)

EPS1.09	<b>Burden and stress among caregivers of adults with CF during lung transplant deliberation</b>	14:48 - 14:54
---------	---	---------------

*Oral ePoster presenter:* Tijana Milinic (Seattle, United States)

EPS1.10	<b>Assessment of cognitive performances in cystic fibrosis adult patients</b>	14:54 - 15:00
---------	---	---------------

*Oral ePoster presenter:* Paola Iacotucci (Naples, Italy)

*ePoster Session*

14:00 - 15:00

**EPS 2 - ePoster Session 2 - New topics in cystic fibrosis epidemiology***Leader:* Mette Frahm Olsen (Copenhagen Ø, Denmark)*Leader:* Dominique Zomer-van Ommen (Baarn, Netherlands)

- |         |   |               |
|---------|---|---------------|
| EPS2.01 | <b>Challenges in evaluating the Long-term effectiveness of cystic fibrosis modulator therapies after rapid and widespread adoption: a dual-approach study</b> | 14:00 - 14:06 |
|---------|---|---------------|

*Oral ePoster presenter:* Pedro Miranda Afonso (Rotterdam, Netherlands)

- |         |  |               |
|---------|--|---------------|
| EPS2.02 | <b>A new approach to project survival curves by birth cohort in people with cystic fibrosis, drawing on fifty years of experience in Brittany (Western France)</b> | 14:06 - 14:12 |
|---------|--|---------------|

*Oral ePoster presenter:* Julie Derrien (Brest, France)

- |         |   |               |
|---------|---|---------------|
| EPS2.03 | <b>Highly-effective CFTR modulation and lung development by age, gender, and height among children with cystic fibrosis</b> | 14:12 - 14:18 |
|---------|---|---------------|

*Oral ePoster presenter:* Elizabeth Baker (Birmingham, United States)

- |         |  |               |
|---------|--|---------------|
| EPS2.04 | <b>Concordance of self-reported chronic daily therapy use with the cystic fibrosis foundation patient registry</b> | 14:18 - 14:24 |
|---------|--|---------------|

*Oral ePoster presenter:* Cynthia Brown (Indianapolis, United States)

- |         |   |               |
|---------|---|---------------|
| EPS2.05 | <b>LONGITUDE-Non-F: an observational study evaluating outcomes of ELX/TEZ/IVA in people with cystic fibrosis aged <math>\geq 6</math> years with non-F508del CFTR variants using data from the UK CF Registry</b> | 14:24 - 14:30 |
|---------|---|---------------|

*Oral ePoster presenter:* Carl A Baxter (Boston, United States)

- |         |   |               |
|---------|---|---------------|
| EPS2.06 | <b>Exploring the diversity of nontuberculous mycobacteria in cystic fibrosis centers across the U.S.: Lessons from the prospective HALT study</b> | 14:30 - 14:36 |
|---------|---|---------------|

*Oral ePoster presenter:* Jane E. Gross (Chapel Hill, United States)

- |         |  |               |
|---------|--|---------------|
| EPS2.07 | <b>Assessment of the impact of the new born screening programme on growth and <i>Pseudomonas aeruginosa</i> infection in children with cystic fibrosis in Ireland: the Irish Comparative Outcomes Study (ICOS)</b> | 14:36 - 14:42 |
|---------|--|---------------|

*Oral ePoster presenter:* Patricia Fitzpatrick (Dublin, Ireland)

- |         |  |               |
|---------|--|---------------|
| EPS2.08 | <b>This study explores unmet needs and insecurity among people with cystic fibrosis living in earthquake-affected zones of Turkiye, conducted as a multicenter study</b> | 14:42 - 14:48 |
|---------|--|---------------|

*Oral ePoster presenter:* Şeyda Karabulut (Istanbul, Turkey)

- |         |  |               |
|---------|--|---------------|
| EPS2.09 | <b>Sustainable effect of elaxacaftor/tezacaftor/ivacaftor on FEV1 and LCI over 2 years</b> | 14:48 - 14:54 |
|---------|--|---------------|

*Oral ePoster presenter:* Andreas Jung (Zurich, Switzerland)

- |         |   |               |
|---------|---|---------------|
| EPS2.10 | <b>Transitioning to race-neutral reference equations on lung function for people with cystic fibrosis: which consequences for Europe?</b> | 14:54 - 15:00 |
|---------|---|---------------|

*Oral ePoster presenter:* Anna Zolin (Milano, Italy)*ePoster Session*

14:00 - 15:00

**EPS 3 - ePoster Session 3 - Lessons from cell and animal models***Leader:* Carlos M Farinha (Lisboa, Portugal)*Leader:* Valeria Tomati (Genoa, Italy)

- |         |   |               |
|---------|---|---------------|
| EPS3.01 | <b>CFTR rescue in a G542X nonsense mouse model of cystic fibrosis: investigating the mechanism of action and activity of translational readthrough-inducing drugs</b> | 14:00 - 14:06 |
|---------|---|---------------|

*Oral ePoster presenter:* Emanuele Vitale (Palermo, Italy)

- |         |   |               |
|---------|---|---------------|
| EPS3.02 | <b>A preferential orientation adipocyte differentiation of CFTR-mutated mesenchymal stem cells: predisposing factor to cystic</b> | 14:06 - 14:12 |
|---------|---|---------------|

**fibrosis-related bone diseases**

*Oral ePoster presenter:* Laurine Hamon (Reims, France)

EPS3.03      **Investigating the involvement of osteocytes in cystic fibrosis-related bone disease: setting up innovative models**      14:12 - 14:18

*Oral ePoster presenter:* Léa Thoraval (Reims, France)

EPS3.04      **Development of therapeutic strategies to promote epithelial repair and regeneration in cystic fibrosis preclinical models of primary airway and alveolar cultures and living lung tissues**      14:18 - 14:24

*Oral ePoster presenter:* Emmanuelle Brochiero (Montréal, Canada)

EPS3.05      **Comparison of CFTR-mediated ion transport in air-liquid interface cultures derived from healthy and cystic fibrosis patients using electrophysiological and cellular analysis methods**      14:24 - 14:30

*Oral ePoster presenter:* Roshani Narayan Singh (Muenster, Germany)

EPS3.06      **Mitochondrial metabolic rewiring drives wound healing in cystic fibrosis primary airway epithelium cultures treated with ellexacaftor/tezacaftor/ivacaftor**      14:30 - 14:36

*Oral ePoster presenter:* Mairead Kelly-Aubert (Paris, France)

EPS3.07      **Functional rescue of the I506T-CFTR variant by CFTR modulator combination therapies in human nasal epithelial cell-derived air-liquid interface cultures**      14:36 - 14:42

*Oral ePoster presenter:* Naomi Potter (Vancouver, Canada)

EPS3.08      **A comparative study of a novel microbially derived pancreatic enzymes mixture (ANG003) and porcine pancrelipase (Creon) effects on coefficient of fat absorption in exocrine pancreatic insufficient pig**      14:42 - 14:48

*Oral ePoster presenter:* Kateryna Pierzynowska (Lund, Sweden)

EPS3.09      **Regulation of glucose homeostasis by meal macronutrients and exogenous enzymes; studies on healthy and exocrine pancreatic insufficient pigs**      14:48 - 14:54

*Oral ePoster presenter:* Kateryna Pierzynowska (Lund, Sweden)

EPS3.10      **Mapping the impact of ETI-mediated CFTR reactivation on development: a zebrafish model study**      14:54 - 15:00

*Oral ePoster presenter:* Anna Pistocchi (Milano, Italy)

*ePoster Session*

14:00 - 15:00

**EPS 4 - ePoster Session 4 - Gut reactions: A future with less disease?**

*Leader:* Michael Wilschanski (Jerusalem, Israel)

*Leader:* Inger Hee Mabuza Mathiesen (Copenhagen, Denmark)

EPS4.01      **Pancreatic insufficiency is no longer permanent: a new reality**      14:00 - 14:06

*Oral ePoster presenter:* Hanne Vebert Olesen (Aarhus N, Denmark)

EPS4.02      **Impact of ETI therapy on liver stiffness: a longitudinal study in children and adults**      14:06 - 14:12

*Oral ePoster presenter:* Alexander Rüggeberg (Jena, Germany)

EPS4.03      **Improved liver stiffness after initiation of ellexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A 7-year cohort study**      14:12 - 14:18

*Oral ePoster presenter:* Carolin Steinack (Zurich, Switzerland)

EPS4.04      **Impact of ellexacaftor-tezacaftor-ivacaftor (ETI) And lumacaftor-ivacaftor (LI) On liver health in children with cystic fibrosis: a multicenter observational study**      14:18 - 14:24

*Oral ePoster presenter:* Maha Naamaoui (Paris, France)



EPS4.05	<b>CF Tummy Tracker: development of a cystic fibrosis-specific patient reported outcome measure for daily gastrointestinal symptom burden</b>	14:24 - 14:30
<i>Oral ePoster presenter:</i> Alan R. Smyth (Nottingham, United Kingdom)		
EPS4.06	<b>Antibiotic resistance genes in stool samples from adults with cystic fibrosis: preliminary analysis</b>	14:30 - 14:36
<i>Oral ePoster presenter:</i> Laura R. Caley (Leeds, United Kingdom)		
EPS4.07	<b>Plasma and stool metabolomic profiles in people with cystic fibrosis and inflammatory bowel disease compared with healthy controls using nuclear magnetic resonance</b>	14:36 - 14:42
<i>Oral ePoster presenter:</i> Pauline Sadrieh (Brandenburg an der Havel, Germany)		
EPS4.08	<b>Positive gastrointestinal outcomes of elexacaftor/tezacaftor/ivacaftor therapy in CF patients carrying the F508del mutation: results of a multicenter prospective study</b>	14:42 - 14:48
<i>Oral ePoster presenter:</i> Liron Birimberg-Schwartz (Jerusalem, Israel)		
EPS4.09	<b>The gut's role in pulmonary and extrapulmonary manifestation of cystic fibrosis</b>	14:48 - 14:54
<i>Oral ePoster presenter:</i> Alessandra Bragonzi (Milano, Italy)		
EPS4.10	<b>Impact of elexacaftor-tezacaftor-ivacaftor treatment on the cystic fibrosis hepatobiliary involvement score over time</b>	14:54 - 15:00
<i>Oral ePoster presenter:</i> Stephanie Van Biervliet (Ghent, Belgium)		
<i>Poster Viewing</i> 14:00 - 15:00		
<b>Poster Viewing 1</b>		
P001	<b>The correlation of polymorphism of xenobiotic metabolism genes with indicators of efficacy and safety of CFTR modulator therapy</b>	14:00 - 14:00
<i>Poster author:</i> Elena Kondratyeva (Moscow, Russian Federation)		
P002	<b>Clinical and functional characteristics of carriers of complex alleles of the CFTR gene and targeted therapy</b>	14:00 - 14:00
<i>Poster author:</i> Yuliya Melyanovskaya (Moscow, Russian Federation)		
P003	<b>A complex allele that impairs response to ETI</b>	14:00 - 14:00
<i>Poster author:</i> Mélissa Baravalle Einaudi (Marseille Ced 05, France)		
P004	<b>Investigating the distribution and frequency of CFTR alleles in Wales using linked data</b>	14:00 - 14:00
<i>Poster author:</i> Robert T. Maddison (Cardiff, United Kingdom)		
P006	<b>Spectrum of CFTR genetic variants among children with cystic fibrosis in Kazakhstan</b>	14:00 - 14:00
<i>Poster author:</i> Elena Amelina (Astana, Kazakhstan)		
P007	<b>Genetic profile of cystic fibrosis in Morocco</b>	14:00 - 14:00
<i>Poster author:</i> Anass HAFIF (Casablanca, Morocco)		
P008	<b>Large deletions account for about 4% of our patients with CF - should we include MLPA in newborn screening?</b>	14:00 - 14:00
<i>Poster author:</i> Guergana Petrova (Sofia, Bulgaria)		
P009	<b>CFTR gene variants in the group of adult cystic fibrosis patients in Kazakhstan</b>	14:00 - 14:00
<i>Poster author:</i> Elena Amelina (Astana, Kazakhstan)		
P010	<b>The evaluation of the genotype and phenotype relationship in patients with nasal polyps in the National Cystic Fibrosis Registry</b>	14:00 - 14:00
<i>Poster author:</i> Handan Kekec (Ankara, Turkey)		

P012	<b>Implementation of the automated <math>\beta</math>-adrenergic Sweat Secretion Test in patients with inconclusive CFTR genetics and sweat chloride concentration</b>	14:00 - 14:00
<i>Poster author:</i> Sophia Pallenberg (Hannover, Germany)		
P013	<b>Understanding of sweat testing amongst adults living with cystic fibrosis: we've got work to do but don't sweat it</b>	14:00 - 14:00
<i>Poster author:</i> Nikolas Johl (Cardiff, United Kingdom)		
P014	<b>CFTRdup15-22: a new CFTR macro-duplication associated with cystic fibrosis in a newborn screening case</b>	14:00 - 14:00
<i>Poster author:</i> Giovanna Blaonà (Rome, Italy)		
P015	<b>Development of new Magnetic Resonance Imaging and Spectroscopy techniques to diagnose fat malabsorption</b>	14:00 - 14:00
<i>Poster author:</i> Arantxa Recto (Nottingham, United Kingdom)		
P016	<b>Computerized tomography scoring does predict exacerbations and decrease in pulmonary functions in cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Oğuz Karcıoğlu (Ankara, Turkey)		
P017	<b>Comparison of different reference values of spirometry parameters in adult patients with cystic fibrosis in Russia</b>	14:00 - 14:00
<i>Poster author:</i> Stanislav Krasovsky (Moscow, Russian Federation)		
P018	<b>Single measurement quantification and modeling of elexafactor, tezacaftor and ivacaftor in adults: overlap between full and reduced dosing</b>	14:00 - 14:00
<i>Poster author:</i> Silvia Caceres (Denver, United States)		
P019	<b>Evaluation of professional quality of life and prevalence of burnout: a national survey of healthcare providers on cystic fibrosis care teams</b>	14:00 - 14:00
<i>Poster author:</i> Alexandra L. Quittner (Hollywood, United States)		
P020	<b>Comparing impulse oscillometry in primary ciliary dyskinesia, cystic fibrosis, and healthy preschool-age children</b>	14:00 - 14:00
<i>Poster author:</i> Burcu Capraz Yavuz (Ankara, Turkey)		
P021	<b>Colorectal cancer screening in cystic fibrosis lung transplant recipients in Ireland</b>	14:00 - 14:00
<i>Poster author:</i> Robert Hughes (Dublin 7, Ireland)		
P022	<b>MBW in cystic fibrosis: how experience shapes test quality</b>	14:00 - 14:00
<i>Poster author:</i> Ana Margarida Silva (Lisbon, Portugal)		
P023	<b>A unique case of cystic fibrosis and Lane-Hamilton syndrome: implications for diagnosis and management</b>	14:00 - 14:00
<i>Poster author:</i> Andrea Párnitzky (Budapest, Hungary)		
P024	<b>Electrolyte imbalance and pseudo-Bartter syndrome in infants with cystic fibrosis (CF): a rare manifestation of CF</b>	14:00 - 14:00
<i>Poster author:</i> Burak Uslu (Dresden, Germany)		
P025	<b>Preliminary analysis of Slovenia's national pilot newborn cystic fibrosis screening program using the IRT/PAP/DNA protocol</b>	14:00 - 14:00
<i>Poster author:</i> Uros Krivec (Ljubljana, Slovenia)		
P026	<b>Five-year evaluation of the cystic fibrosis Newborn Screening Program in the city of Buenos Aires</b>	14:00 - 14:00
<i>Poster author:</i> Alejandro Teper (Buenos Aires, Argentina)		
P027	<b>A ten-year outcome of cystic fibrosis newborn screening programme at Hacettepe University, Türkiye</b>	14:00 - 14:00
<i>Poster author:</i> Umay Kavgaci (Ankara, Turkey)		

P028	<b>Cystic fibrosis newborn screening in Luxembourg: 7 years' experience</b>	14:00 - 14:00
<i>Poster author:</i> Anna-Maria Charatsi (Luxembourg, Luxembourg)		
P029	<b>Newborn screening for cystic fibrosis in North Macedonia</b>	14:00 - 14:00
<i>Poster author:</i> Elena Krsteska (Skopje, North Macedonia)		
P030	<b>Genetic testing in the new algorithm of neonatal screening for cystic fibrosis. Implementation experience on the example of the Moscow region</b>	14:00 - 14:00
<i>Poster author:</i> Tatiana Kyian (Moscow, Russian Federation)		
P031	<b>Cystic fibrosis: two years of expanded newborn screening in Ukraine</b>	14:00 - 14:00
<i>Poster author:</i> Svitlana Kormoz (Kyiv, Ukraine)		
P032	<b>Effectiveness of newborn screening for cystic fibrosis over 18 years of implementation in the Moscow region</b>	14:00 - 14:00
<i>Poster author:</i> Irina Fatkhullina (Moscow, Russian Federation)		
P033	<b>The impact of newborn bloodspot screening program modification in 2023 on the time of diagnosis in cystic fibrosis patients and follow-up care</b>	14:00 - 14:00
<i>Poster author:</i> Lukasz Wozniacki (Warsaw, Poland)		
P034	<b>Cystic fibrosis screen positive, inconclusive diagnosis (CFSPID) Diagnosed during the first three years of newborn screening in Norway</b>	14:00 - 14:00
<i>Poster author:</i> Magnhild Kolsgaard (Oslo, Norway)		
P035	<b>Generally positive clinical outcomes of CFSPID cases identified between 2009 and 2023 within the nationwide neonatal screening programme in the Czech Republic</b>	14:00 - 14:00
<i>Poster author:</i> Jana Bartošová (Prague 5, Czech Republic)		
P036	<b>CF carriers identified during the algorithm of neonatal screening IRT/DNA in the Moscow region</b>	14:00 - 14:00
<i>Poster author:</i> Vera Shadrina (Mytishchi, Moscow region, Russian Federation)		
P037	<b>Evaluation of infants referred due to positive cystic fibrosis newborn screening results: ten years single center experience</b>	14:00 - 14:00
<i>Poster author:</i> Nazan Cobanoglu (Ankara, Turkey)		
P038	<b>Characteristics of children with cystic fibrosis not detected in newborn screening due to low IRT values and a comparison with the patient group detected through screening</b>	14:00 - 14:00
<i>Poster author:</i> Raziye Atan (Ankara, Turkey)		
P039	<b>Information resources on cystic fibrosis newborn diagnosis to support parents/carers</b>	14:00 - 14:00
<i>Poster author:</i> Alison Taylor (London, United Kingdom)		
P040	<b>Differing approaches to the management of children with a Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) designation across the North West of England</b>	14:00 - 14:00
<i>Poster author:</i> Charlie Jeffkins (Liverpool, United Kingdom)		
P041	<b>Developing new cystic fibrosis staffing guidelines amid evolving care in Canada</b>	14:00 - 14:00
<i>Poster author:</i> Jana Kocourek (Toronto, Canada)		
P043	<b>Innovative approaches in cystic fibrosis: development of prime editing-based gene therapy for F508del CFTR variant</b>	14:00 - 14:00
<i>Poster author:</i> Olga Volodina (Moscow, Russian Federation)		
P045	<b>Epigenetic control of CFTR and FOXI1 gene expression in cystic</b>	14:00 - 14:00

**fibrosis**

Poster author: Giovanna Blaçonà (Rome, Italy)

P046 **Investigating the safety of elexacaftor/tezacaftor/ivacaftor exposure during early development** 14:00 - 14:00

Poster author: Angelica Squarizoni (Genova, Italy)

P047 **Can clinical parameters replace hypoxic challenge testing?** 14:00 - 14:00

Poster author: Shahna Shameem (Manchester, United Kingdom)

P048 **An LC-MS method for detection of CFTR protein *in vitro* and in pulmonary tissues** 14:00 - 14:00

Poster author: Joseph Chen (Menlo Park, CA, United States)

P049 **Theranostics for ultra-rare variants of CFTR gene: a case study of L999del** 14:00 - 14:00

Poster author: Tereza Doušová (Prague, Czech Republic)

P050 **Design of a Phase 2 study in 3849 +10 Kb C->T CF patients to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SPL84** 14:00 - 14:00

Poster author: Lital Friedman (Jerusalem, Israel)

P051 **Comparability assessment of two nebulizers, supporting clinical use expansion for SPL84, an ASO for treatment of CF patients carrying the 3849+10 Kb C->T mutation** 14:00 - 14:00

Poster author: Gili Hart (Jerusalem, Israel)

P052 **Biodistribution of lipid nanoparticle-delivered HA-CFTR mRNA in well-differentiated cystic fibrosis bronchial epithelial cultures and its translational relevancy *in vivo*** 14:00 - 14:00

Poster author: Joseph Chen (Menlo Park, CA, United States)

P053 **Elaboration of a method for determining concentrations and pharmacokinetic parameters of tezacaftor, lumacaftor, ivacaftor and elexacaftor in the blood plasma of patients with cystic fibrosis** 14:00 - 14:00

Poster author: Elena Kondratyeva (Moscow, Russian Federation)

P054 **Pre-dose plasma concentrations of elexacaftor, tezacaftor and ivacaftor in people with cystic fibrosis: a real-world observational study** 14:00 - 14:00

Poster author: Adrienn Banki (Stockholm, Sweden)

P056 **Improved small airway function in children with cystic fibrosis treated with the triple combination elexacaftor/tezacaftor/ivacaftor: results of real world multicenter observational study** 14:00 - 14:00

Poster author: Lucie COLIN (Lyon, France)

P057 **Efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying non-F508del variants in a Portuguese Reference Center** 14:00 - 14:00

Poster author: Susana Castanhinha (Lisboa, Portugal)

P058 **Significant correction of CFTR function improves clinical and biological measures in infants and young children: BEGIN study** 14:00 - 14:00

Poster author: Lucas Hoffman (Seattle, United States)

P059 **Effects of CFTR modulator triple therapy elexacaftor/tezacaftor/ivacaftor in paediatric cystic fibrosis patients aged 2 to 5 years** 14:00 - 14:00

Poster author: Teresa Ramos (Madrid, Spain)

P060 **Evaluation of the efficacy of targeted therapy on different genotypes of patients with cystic fibrosis (CF): experience of the Federal Centre** 14:00 - 14:00

Poster author: Yulia Gorinova (Moscow, Russian Federation)

P061	<b>Monitoring the effectiveness of elexacaftor/tezacaftor/ivacaftor therapy in children and adolescents with cystic fibrosis and normal spirometry</b>	14:00 - 14:00
<i>Poster author:</i> Gianfranco Alicandro (Milan, Italy)		
P062	<b>The effect of gradual increase in control visit intervals on essential primary endpoints in children 2-18 year old with CF on ETI therapy</b>	14:00 - 14:00
<i>Poster author:</i> Alexander Rotenberg (Odense M, Denmark)		
P063	<b>Effectiveness of ETI in people with cystic fibrosis &amp; rare <i>CFTR</i> variants</b>	14:00 - 14:00
<i>Poster author:</i> María Alejandra Rey (Montevideo, Uruguay)		
P064	<b>The benefits of elexacaftor/tezacaftor/ivacaftor to individuals homozygous for the N1303K variant</b>	14:00 - 14:00
<i>Poster author:</i> Helga Elíðóttir (Reykjavik, Iceland)		
P065	<b>Approval of elexacaftor/tezacaftor/ivacaftor for children with CF - first experiences under “real life” conditions of a German CF center</b>	14:00 - 14:00
<i>Poster author:</i> Jan Thomassen (Cologne, Germany)		
P066	<b>The first experience of triple targeted therapy in adult patients with cystic fibrosis in Kazakhstan</b>	14:00 - 14:00
<i>Poster author:</i> Irina Mukatova (Astana, Kazakhstan)		
P067	<b>First clinical experience with elexacaftor/tezacaftor/ivacaftor at Adult Cystic Fibrosis Centre in Lithuania</b>	14:00 - 14:00
<i>Poster author:</i> Kestutis Malakauskas (Kaunas, Lithuania)		
P068	<b>Efficacy of <i>CFTR</i> modulator elexacaftor/tezacaftor/ivacaftor in the Russian population of patients with cystic fibrosis after 12-month therapy in different age groups</b>	14:00 - 14:00
<i>Poster author:</i> Elena Kondratyeva (Moscow, Russian Federation)		
P069	<b>Real-world experience with elexacaftor/tezacaftor/ivacaftor in Uruguayan adults with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> María Alejandra Rey (Montevideo, Uruguay)		
P070	<b>Sweet chloride concentration in patients before and during treatment with <i>CFTR</i> modulators</b>	14:00 - 14:00
<i>Poster author:</i> Elena Gjinojska-Tasevska (Skopje, North Macedonia)		
P071	<b>The all Wales adult cystic fibrosis centre experience of patient sweat test changes on ETI therapy</b>	14:00 - 14:00
<i>Poster author:</i> Nikolas Johl (Cardiff, United Kingdom)		
P072	<b>Improvement of the sweat test report designed for CF patients on modulators</b>	14:00 - 14:00
<i>Poster author:</i> Natalia Cirilli (Ancona, Italy)		
P073	<b>Effects of elexacaftor/tezacaftor/ivacaftor on <i>CFTR</i> function in children with CF aged 2-11 years</b>	14:00 - 14:00
<i>Poster author:</i> Simon Y. Graeber (Berlin, Germany)		
P074	<b>Can sweat chloride levels serve as a biomarker for clinical response to elexacaftor/tezacaftor/ivacaftor in cystic fibrosis patients?</b>	14:00 - 14:00
<i>Poster author:</i> Elena Krsteska (Skopje, North Macedonia)		
P075	<b>Guts N' Noses. Relating gastrointestinal (CFAbd-Score) and sinonasal (SNOT) effects of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Jochen G. Mainz (Brandenburg an der Havel, Germany)		
P076	<b>The effects of modulator therapy on pulmonary function and BMI in adult patients with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Tanja Savin (Skopje, North Macedonia)		

P077	<b>Microgallbladder disappearance in two cystic fibrosis patients during cystic fibrosis transmembrane conductance regulator modulators</b>	14:00 - 14:00
<i>Poster author:</i> Ivan Bambir (Zagreb, Croatia)		
P078	<b>Aquagenic wrinkling of the palms in cystic fibrosis patients treated with cystic fibrosis transmembrane conductance regulator modulators</b>	14:00 - 14:00
<i>Poster author:</i> Ivan Bambir (Zagreb, Croatia)		
P079	<b>Examining elexacaftor/tezacaftor/ivacaftor (ETI) treatment regimens: findings from the yETI study</b>	14:00 - 14:00
<i>Poster author:</i> Christine Ford (Baltimore, United States)		
P080	<b>Quality of life perception upon therapy with elexacaftor/tezacaftor/ivacaftor as evaluated by children aged 6 to 13 and their caregivers</b>	14:00 - 14:00
<i>Poster author:</i> Francesca Buniotto (Verona, Italy)		
P082	<b>Quality of life in school age patients after treatment with elexacaftor/tezacaftor/ivacaftor (ETI)</b>	14:00 - 14:00
<i>Poster author:</i> Isabell Ricklefs (Lübeck, Germany)		
P083	<b>Changes in health-related quality of life after the introduction of triple-modulator therapy in cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Maria Hein Hegelund (Copenhagen, Denmark)		
P084	<b>Neuro-behavioural issues after initiating elexacaftor/tezacaftor/ivacaftor (ETI) In preschool-age children with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Alanood Alagedi (London, United Kingdom)		
P085	<b>Adverse events resulting from CFTR modulator therapy in children with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Dana Teodora Anton Paduraru (Iasi, Romania)		
P086	<b>Analysis of age-related features of adverse events when using lumacaftor/ivacaftor in paediatric patients of the Russian Federation</b>	14:00 - 14:00
<i>Poster author:</i> Elena Kondratyeva (Moscow, Russian Federation)		
P087	<b>Behavioural and health impacts of ETI therapy in preschool-aged CF children</b>	14:00 - 14:00
<i>Poster author:</i> Maria Day (Southampton, United Kingdom)		
P088	<b>Exploration of a putative implication of cytochrome P450 genetic polymorphism in elexacaftor/tezacaftor/ivacaftor side effects</b>	14:00 - 14:00
<i>Poster author:</i> Sophie Ramel (Roscoff, France)		
P089	<b>Analysis of age-related features of adverse events when using elexacaftor/tezacaftor/ivacaftor in paediatric patients of the Russian Federation</b>	14:00 - 14:00
<i>Poster author:</i> Elena Kondratyeva (Moscow, Russian Federation)		
P090	<b>Exploring the adherence to treatment with elexacaftor/tezacaftor/ivacaftor (ETI) In people with cystic fibrosis: a retrospective, dual-center observational study</b>	14:00 - 14:00
<i>Poster author:</i> Angela Pepe (Potenza, Italy)		
P091	<b>Pharmacokinetic of elexacaftor/tezacaftor/ivacaftor in the context of fetal cystic fibrosis therapy</b>	14:00 - 14:00
<i>Poster author:</i> Ngoc Hoa Truong (Paris, France)		
P092	<b>First report of continuous administration of elexacaftor/tezacaftor/ivacaftor from in utero to 1 year of age</b>	14:00 - 14:00
<i>Poster author:</i> Anne Mornand (Geneva, Switzerland)		

P093	<b>The modulator baby boom - a retrospective review of pregnancies and neonates with in-utero exposure to highly effective modulator therapy in the West of Scotland</b>	14:00 - 14:00
<i>Poster author:</i> Nicola Jane Robinson (Glasgow, United Kingdom)		
P094	<b>The experience of using triple targeted therapy in a patient with cystic fibrosis complicated by cystic fibrosis-related diabetes</b>	14:00 - 14:00
<i>Poster author:</i> Mikhail Chaplanov (Ryazan, Russian Federation)		
P095	<b>First results of dual targeted therapy in adult patients with cystic fibrosis in Kazakhstan</b>	14:00 - 14:00
<i>Poster author:</i> Saltanat Kim (Astana, Kazakhstan)		
P096	<b>Virtual consultations to provide multidisciplinary support for women with cystic fibrosis in the post-natal period</b>	14:00 - 14:00
<i>Poster author:</i> Georgie Goodwin (Newcastle upon Tyne, United Kingdom)		
P097	<b>Elevated liver function tests in infants exposed to elxacaftor/tezacaftor/ivacaftor in utero and while breastfeeding - case report series from 4 mother-infant pairs</b>	14:00 - 14:00
<i>Poster author:</i> Theresa Kolaczowski (Southampton, United Kingdom)		
P098	<b>Metabolic and excretion profiles of the FAIR therapeutics CFTR modulators nesolicaftor, posenacaftor and dirocaftor in humans (healthy volunteers)</b>	14:00 - 14:00
<i>Poster author:</i> Paraskevi Charitou (Oss, Netherlands)		
P099	<b><sup>14</sup>C recovery of the FAIR Therapeutics CFTR modulators Nesolicaftor, Posenacaftor and Dirocaftor in Sprague Dawley rats</b>	14:00 - 14:00
<i>Poster author:</i> Paraskevi Charitou (Oss, Netherlands)		
P100	<b>Adverse events related to study drugs in finding the optimal regimen for <i>Mycobacterium abscessus</i> treatment (FORMaT) trial</b>	14:00 - 14:00
<i>Poster author:</i> Claire Wainwright (Brisbane, Australia)		
P101	<b>Prevalence of nausea and vomiting and anti-emetic use in the finding the optimal regimen for <i>Mycobacterium abscessus</i> treatment (Format) trial</b>	14:00 - 14:00
<i>Poster author:</i> Claire Wainwright (Brisbane, Australia)		
P102	<b>Phage therapy: a new era of healing</b>	14:00 - 14:00
<i>Poster author:</i> Susana Castanhinha (Lisbon, Portugal)		
P103	<b>Adding oxygen to enhance antibiotic treatment of chronic lung infection (AdOx)</b>	14:00 - 14:00
<i>Poster author:</i> Mette Kolpen (Copenhagen, Denmark)		
P104	<b>CF-AMR Syndicate Collaborative Discovery Programme to accelerate the development of antimicrobials to treat lung infections in cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Lesley Jenkinson (Macclesfield, United Kingdom)		
P105	<b>YOGA-CF: stretching boundaries - an ongoing real-world randomised controlled trial, maximising trial participation and involving the wider multidisciplinary team</b>	14:00 - 14:00
<i>Poster author:</i> Gemma. E. Stanford (London, United Kingdom)		
P106	<b>Inhalation therapy matters - results from the trial „conneCT CF-coaching and telemedicine in patients with cystic fibrosis"</b>	14:00 - 14:00
<i>Poster author:</i> Stephanie Thee (Berlin, Germany)		
P107	<b>A randomized controlled study of sildenafil to treat exercise intolerance in people with moderate to severe cystic fibrosis lung disease</b>	14:00 - 14:00
<i>Poster author:</i> Jennifer L. Taylor-Cousar (Denver, United States)		

P108	<b>Clinical Effort Against Smoke Exposure in CF (CEASE-CF): impact on hair nicotine levels in children with CF</b>	14:00 - 14:00
<i>Poster author:</i> William Harris (Birmingham, United States)		
P109	<b>Development of a universal core outcome set for cystic fibrosis (COS-CF): protocol and systematic review</b>	14:00 - 14:00
<i>Poster author:</i> Bethinn C Evans (Belfast, United Kingdom)		
P110	<b>10 Years of the ECFS Lung Clearance Index (LCI) core facility - achievements and future directions</b>	14:00 - 14:00
<i>Poster author:</i> Mary Abkir (London, United Kingdom)		
P111	<b>Patient and caregiver preferences in cystic fibrosis: a qualitative patient preference study to identify contemporary patient-relevant clinical endpoints and inclusion criteria</b>	14:00 - 14:00
<i>Poster author:</i> Jorge Madrid Paredes (Leuven, Belgium)		
P112	<b>Prevalence of dyslipidemia in a diverse population of adults with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Gianmarco Putti		
P113	<b>Overcoming hurdles in initiating and conducting future innovative clinical trials in CF: insights from recent experience</b>	14:00 - 14:00
<i>Poster author:</i> Marlies Destoop (Utrecht, Netherlands)		
P114	<b>Academic clinical trials in cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Fiona Dunlevy (Karup, Denmark)		
P115	<b>Protocols under patient/community scrutiny: the good, the bad and the confusing</b>	14:00 - 14:00
<i>Poster author:</i> Anne Verbrugge (Leuven, Belgium)		
P116	<b>The clinical trials accelerator platform; a UK clinical trials network at the forefront of advancing new treatments for cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Rebecca Brendell (London, United Kingdom)		
P117	<b>Updating cystic fibrosis standards of care guidelines for care of children and adults in the UK</b>	14:00 - 14:00
<i>Poster author:</i> Jessica Denning (London, United Kingdom)		
P118	<b>Community engagement and involvement in clinical trials and beyond...</b>	14:00 - 14:00
<i>Poster author:</i> Claire Walter (London, United Kingdom)		
P119	<b>This pilot study investigated home monitoring and video consultation for children with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Maria Nøregård Jørgensen (Copenhagen, Denmark)		
P120	<b>Patients' perception of a self-management app to improve medication adherence in cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Lea Botermann (Starnberg, Germany)		
P121	<b>Bridging the gap. Translated CF medical education to support CF centres from the ECFS/CFE Twinning project</b>	14:00 - 14:00
<i>Poster author:</i> Chris Smith (Brighton, United Kingdom)		
P122	<b>Development and application of a LC-MS/MS method for monitoring CFTR modulators in biological fluids: a step forward in personalized cystic fibrosis treatment</b>	14:00 - 14:00
<i>Poster author:</i> Matteo Mucci (Chieti, Italy)		
P123	<b>Evaluating pulmonologists' accuracy in visually estimating lung function trends in cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Marcus Svedberg (Göteborg, Sweden)		
P124	<b>The role of forced oscillometry technique in monitoring lung</b>	14:00 - 14:00



	<b>function of paediatric cystic fibrosis patients on elexacaftor/tezacaftor/ivacaftor therapy</b>	
	<i>Poster author:</i> Chiara Cimbalo (Napoli, Italy)	
P125	<b>Online survey of perspectives on lung imaging use in cystic fibrosis</b>	14:00 - 14:00
	<i>Poster author:</i> Daniel Beever (Nottingham, United Kingdom)	
P126	<b>Diagnostic accuracy of impulse oscillometer indices in children with cystic fibrosis and primary ciliary dyskinesia</b>	14:00 - 14:00
	<i>Poster author:</i> Burcu Capraz Yavuz (Ankara, Turkey)	
P127	<b>Oscillometry in CF children with normal spirometry</b>	14:00 - 14:00
	<i>Poster author:</i> Larry Lands (Montreal, Canada)	
P128	<b>Triple combination elexacaftor/tezacaftor/ivacaftor and Bhalla score in cystic fibrosis patient</b>	14:00 - 14:00
	<i>Poster author:</i> Alain Palem (Liege, Belgium)	
P130	<b>Factors affecting lung function and bronchodilator test result in cystic fibrosis patients</b>	14:00 - 14:00
	<i>Poster author:</i> Oksana Kositskaya (Moscow, Russian Federation)	
P131	<b>Systematic review of hyperpolarised 129 xenon MRI scanning in people with cystic fibrosis; assessing the potential uses for clinical and research practice</b>	14:00 - 14:00
	<i>Poster author:</i> Aria Walters (Liverpool, United Kingdom)	
P132	<b>Cystic fibrosis as a modulable model for CFTR-related immune dysregulation</b>	14:00 - 14:00
	<i>Poster author:</i> Leander Jonckheere (Ghent, Belgium)	
P133	<b>Age-dependent changes in inflammatory markers in nasal lavage samples after two years of elexacaftor/tezacaftor/ivacaftor therapy</b>	14:00 - 14:00
	<i>Poster author:</i> Teresa Fuchs (Innsbruck, Austria)	
P134	<b>Long-term reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor in cystic fibrosis</b>	14:00 - 14:00
	<i>Poster author:</i> Rebecca Dalferth (Hannover, Germany)	
P135	<b>Single-cell RNA sequencing shows that circulating monocytes enriched in IFN signaling are associated with nontuberculous mycobacteria pulmonary disease in cystic fibrosis</b>	14:00 - 14:00
	<i>Poster author:</i> Nicola Lore (Milano, Italy)	
P136	<b>Immunoglobulin A mucosal immunity in people with cystic fibrosis shortly after initiation of highly effective modulators therapy</b>	14:00 - 14:00
	<i>Poster author:</i> Angélique Mottais (Woluwe Saint-Lambert, Belgium)	
P137	<b>Pro-inflammatory role of extracellular nicotinamide phosphoribosyltransferase in cystic fibrosis</b>	14:00 - 14:00
	<i>Poster author:</i> Laura Lori (Genoa, Italy)	
P139	<b>Chronic production of IL-23 activates a functional heterogeneity of IL-17F-producing cells, which untangle the immunological signature in young adult cystic fibrosis patients with early ABPA diagnosis</b>	14:00 - 14:00
	<i>Poster author:</i> Teresa zelante (Perugia, Italy)	
P140	<b>Salivary calprotectin in children with cystic fibrosis - a pilot study</b>	14:00 - 14:00
	<i>Poster author:</i> Ivan Bambir (Zagreb, Croatia)	
P141	<b>Reduction in serum markers of inflammation in people with cystic fibrosis who are chronically infected with <i>Pseudomonas aeruginosa</i> is seen after treatment with elexacaftor/tezacaftor/ivacaftor</b>	14:00 - 14:00
	<i>Poster author:</i> Yashasvi Rajeev (London, United Kingdom)	

P142	<b>Long term effect of elexacaftor/tezacaftor/ivacaftor therapy on the innate immune response of people with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Gloria Sangiorgi (Rome, Italy)		
P143	<b>Antibiotic and anti-inflammatory therapies from bedside to bench: guidelines to support preclinical development</b>	14:00 - 14:00
<i>Poster author:</i> Cristina Cigana (Milan, Italy)		
P145	<b>Evaluation of hyaluronic acid derivates as new anti-inflammatory treatments for cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Chiara Tupini (Ferrara, Italy)		
P146	<b>Neutrophilic biomarkers of inflammation in children with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Guergana Petrova (Sofia, Bulgaria)		
P147	<b>Comparison of the effect of CFTR modulator <i>elexacaftor/tezacaftor/ivacaftor</i> and <i>lumacaftor/ivacaftor</i> via human epididymis protein 4 plasma concentration in p.Phe508del-CFTR homozygous CF patients</b>	14:00 - 14:00
<i>Poster author:</i> Marianna Pócsi (Debrecen, Hungary)		
P148	<b>Twenty-four months adherence to elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Carina M.E. Hansen (Groningen, Netherlands)		
P149	<b>Beyond the lung. Impact of elexacaftor/tezacaftor/ivacaftor on sinonasal disease in children with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Margaux Petitjean (Paris, France)		
P150	<b>Real world study of effect of elexacaftor/tezacaftor/ivacaftor in school age children with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Anais LE (Paris, France)		
P152	<b>Correlation between pulmonary and nutritional outcomes following treatment with ETI (elexacaftor/tezacaftor/ivacaftor) in people with CF</b>	14:00 - 14:00
<i>Poster author:</i> Michal Gur (Haifa, Israel)		
P153	<b>The impact of antibacterial therapy on the health status of adult patients with cystic fibrosis using CFTR modulators</b>	14:00 - 14:00
<i>Poster author:</i> Elena Amelina (Astana, Kazakhstan)		
P154	<b>Long-term changes in plethysmography, antibiotic therapy, and quality of life in cystic fibrosis patients treated with CFTR modulators</b>	14:00 - 14:00
<i>Poster author:</i> Katarzyna Walicka-Serzysko (Warsaw, Poland)		
P155	<b>The impact of stopping standard inhalation therapy in people with cystic fibrosis (pwCF) established on elexacaftor/tezacaftor/ivacaftor (ETI) - a single centre retrospective study</b>	14:00 - 14:00
<i>Poster author:</i> Rachel Gallagher (Frimley, United Kingdom)		
P156	<b>The impact of CFTR modulators on BMI, FEV1, and microbial status in adult patients with cystic fibrosis: An analysis of registry data from 2021 to 2023</b>	14:00 - 14:00
<i>Poster author:</i> Elena Amelina (Astana, Kazakhstan)		
P157	<b>Elexacaftor/tezacaftor/ivacaftor: eligibility, tolerability and indications</b>	14:00 - 14:00
<i>Poster author:</i> Niall Molloy (Newcastle upon Tyne, United Kingdom)		
P158	<b>Analysis of paranasal sinus volumes in patients with cystic fibrosis. The impact of the disease on the development of the paranasal sinuses</b>	14:00 - 14:00

Poster author: Agata Kałużna-Młynarczyk (Poznań, Poland)

P159 **Long COVID in people with cystic fibrosis: a prospective observational study within the Italian Cystic Fibrosis Society** 14:00 - 14:00

Poster author: Carla Colombo (Milano, Italy)

P160 **Ageing with cystic fibrosis: complications, complexity and comorbidities** 14:00 - 14:00

Poster author: Alan Anderson (Newcastle upon Tyne, United Kingdom)

P161 **Survival post-lung transplantation of patients with cystic fibrosis at the All Wales Adult Cystic Fibrosis Centre** 14:00 - 14:00

Poster author: Nikolas Johl (Cardiff, United Kingdom)

P162 **Developing an effective, efficient, timely and patient centred CF service within a lung transplant program for post lung transplant CF care** 14:00 - 14:00

Poster author: Nicola Ronan (Dublin, Ireland)

P163 **The role of pharmacists in cystic fibrosis care: preliminary results from a systematic review** 14:00 - 14:00

Poster author: Sarah Twohig (Cork, Ireland)

P164 **Evaluation of pulmonologists' knowledge regarding reproductive health in cystic fibrosis** 14:00 - 14:00

Poster author: Hande YUCE OZDEMIR (Hatay, Turkey)

P165 **Pregnancy and cystic fibrosis in the era of CFTR modulators-experiences from centre for cystic fibrosis children and adult, UHC Zagreb,Croatia** 14:00 - 14:00

Poster author: Andrea Vukić Dugac (Zagreb, Croatia)

P166 **Particularities of respiratory impairment in cystic fibrosis in children undiagnosed at birth: a moroccan experience** 14:00 - 14:00

Poster author: Naima Amenzoui (Casablanca, Morocco)

P167 **Pulmonary infections due to fungi in the era of CFTR modulator therapy** 14:00 - 14:00

Poster author: Carsten Schwarz (Potsdam, Germany)

P168 **ABPA in the era of CFTR modulator therapy** 14:00 - 14:00

Poster author: Carsten Schwarz (Potsdam, Germany)

P169 **Allergic bronchopulmonary aspergillosis in Turkey - the incidence and identification of risk factors for its development** 14:00 - 14:00

Poster author: Havva İpek Demir (Ankara, Turkey)

P170 **Grip strength, physical activity levels, and body composition in the CFTR modulator era: insights from paediatric cystic fibrosis** 14:00 - 14:00

Poster author: Marcell Imrei (Budapest, Hungary)

P171 **Extrapulmonary treatable traits in adults with cystic fibrosis on triple combination therapy (elexacaftor/tezacaftor/ivacaftor)** 14:00 - 14:00

Poster author: Benjamin Michael Griffiths (Leeds, United Kingdom)

P172 **Recognising shoulder pain in patients with cystic fibrosis is important** 14:00 - 14:00

Poster author: Nicola Hodgson (Manchester, United Kingdom)

P173 **Beyond Modulators: exploring the continued use of complementary therapy (CT) in UK cystic fibrosis (CF) care** 14:00 - 14:00

Poster author: Emma Dixon (London, United Kingdom)

P174 **A retrospective review of lung ultrasound in guiding physiotherapy input for people with cystic fibrosis in an in-patient setting** 14:00 - 14:00

Poster author: Ciara Long (Bristol, United Kingdom)

P175	<b>Impact of elexacaftor/tezacaftor/ivacaftor (ELE/TEZ/IVA) therapy on adults with cystic fibrosis: a 24-month follow-up study from the Verona center</b>	14:00 - 14:00
<i>Poster author:</i> Riccardo Guarise (Verona, Italy)		
P176	<b>Inhaled mannitol use in UK cystic fibrosis practice following roll out of modulator therapy</b>	14:00 - 14:00
<i>Poster author:</i> Penny Galey (Norwich, United Kingdom)		
P177	<b>Impact of virtual assessments on respiratory sample collection in paediatric cystic fibrosis care</b>	14:00 - 14:00
<i>Poster author:</i> Amy Glen (Southampton, United Kingdom)		
P178	<b>Optimising physiotherapy - developing videos to demonstrate physiotherapy techniques for people with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Jessica Denning (London, United Kingdom)		
P179	<b>Impact of CFTR Modulator therapy on CF admissions: trends at Sheffield Children's Hospital (2016-2024)</b>	14:00 - 14:00
<i>Poster author:</i> Hannah Day (Sheffield, United Kingdom)		
P180	<b>The impact of elexacaftor/tezacaftor/ivacaftor on home oxygen provision in the All Wales Adult Cystic Fibrosis Centre (AWACFC) population</b>	14:00 - 14:00
<i>Poster author:</i> Sarah Caunter (Ilandough, United Kingdom)		
P181	<b>Exercise and physiotherapy sessions for pre-schoolers: qualitative feedback on home visits from patients and families</b>	14:00 - 14:00
<i>Poster author:</i> Louisa Wallbridge (Sheffield, United Kingdom)		
P182	<b>Physiotherapy discontinuation in adult patients on highly effective modulator therapy</b>	14:00 - 14:00
<i>Poster author:</i> Guergana Petrova (Sofia, Bulgaria)		
P183	<b>Effectiveness of telerehabilitation-based individual and group exercises on functional capacity in people with cystic fibrosis: a randomized controlled trial</b>	14:00 - 14:00
<i>Poster author:</i> Cigdem Emirza Cilbir (Istanbul, Turkey)		
P184	<b>Comparison of physical activity levels between neurodivergent and neurotypical people with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Sally Louise Kiernan (Manchester, United Kingdom)		
P185	<b>Physical activity challenges and performance in Hungarian children with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Andrea Párnitzky (Budapest, Hungary)		
P186	<b>Understanding exercise in adults with cystic fibrosis in an era of CFTR modulators</b>	14:00 - 14:00
<i>Poster author:</i> Fiona Holmes (Cork, Ireland)		
P187	<b>The effect of tele-exercise on lung function and quality of life among people with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Elpis Hatziagorou (Thessaloniki, Greece)		
P188	<b>A comparative analysis of exercise testing for cystic fibrosis in the UK: who and which tests?</b>	14:00 - 14:00
<i>Poster author:</i> Rachel McDowell (Bath, United Kingdom)		
P189	<b>Objective measurement of physical activity - the experience from a young CF-population</b>	14:00 - 14:00
<i>Poster author:</i> Lisa Wahlgren (Gothenburg, Sweden)		
P190	<b>Developing a marathon training advice resource for people with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Owen Tomlinson (Exeter, United Kingdom)		

P191	<b>Athlete mentorship and the impact on wellbeing in children and young people: a partnership between Great Ormond Street Hospital and Dame Kelly Holmes Trust</b>	14:00 - 14:00
<i>Poster author:</i> Helen Douglas (London, United Kingdom)		
P192	<b>Exercise as an airway clearance technique in cystic fibrosis patients: a pilot randomized controlled study</b>	14:00 - 14:00
<i>Poster author:</i> Benedetta Fabrizzi (Ancona, Italy)		
P193	<b>A survey to review exercise testing practises across paediatric and adult UK cystic fibrosis (CF) centres</b>	14:00 - 14:00
<i>Poster author:</i> Eleanor Rudge (Bristol, United Kingdom)		
P194	<b>Prevalence and impact of voiding dysfunction in children and young adults with cystic fibrosis in the CFTR modulator era</b>	14:00 - 14:00
<i>Poster author:</i> Jasna Rodman Berlot (Ljubljana, Slovenia)		
P195	<b>Experience with the use of the new airway clearance system in children with cystic fibrosis and primary ciliary dyskinesia</b>	14:00 - 14:00
<i>Poster author:</i> Nataliya Kashirskaya (Moscow, Russian Federation)		
P196	<b>Assessment of the effectiveness of adding the Simeox device during an exacerbation of cystic fibrosis - a retrospective study</b>	14:00 - 14:00
<i>Poster author:</i> Katarzyna Warzeszak (Rabka-Zdroj, Poland)		
P197	<b>The accuracy of self-reported adherence to inhaled therapy compared to electronically captured adherence data. A cross-sectional study</b>	14:00 - 14:00
<i>Poster author:</i> Charlotte Clarke (Sheffield, United Kingdom)		
P198	<b>Perceptions of an adherence support clinic for adults with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Jocelyn Choyce (Birmingham, United Kingdom)		
P199	<b>The impact of tailored exercise interventions on exercise capacity, lung function and physical activity adherence in people with cystic fibrosis: a pilot study</b>	14:00 - 14:00
<i>Poster author:</i> Daniel Lavin (London, United Kingdom)		
P200	<b>Mind the gap: identifying the latest physiotherapy research needs from the 5th edition of the Standards of Care and Good Clinical Practice for the Physiotherapy Management of Cystic Fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Helen Douglas (London, United Kingdom)		
P201	<b>A new Pelvic Health Physiotherapy Service at the Manchester Adult cystic fibrosis Centre: an 18 month review</b>	14:00 - 14:00
<i>Poster author:</i> Nicola Hodgson (Manchester, United Kingdom)		
P202	<b>Bucking the trend: the argument for a cystic fibrosis (CF) homecare paediatric physiotherapy service in a modulator era</b>	14:00 - 14:00
<i>Poster author:</i> Emma Dixon (London, United Kingdom)		
P203	<b>Improving quality of airway clearance with a text message</b>	14:00 - 14:00
<i>Poster author:</i> Chloe Worger (London, United Kingdom)		
P204	<b>Spreading the word: championing communication and collaboration - Survey to identify the views and requirements of the ECFS (PhySIIG) membership</b>	14:00 - 14:00
<i>Poster author:</i> Emma Dixon (London, United Kingdom)		
P205	<b>Adult annual reviews at the West Midlands Adult cystic fibrosis Centre (WMACFC): a service improvement project</b>	14:00 - 14:00
<i>Poster author:</i> Jocelyn Choyce (Birmingham, United Kingdom)		
P206	<b>ECFS PhySIIG sponsored Accreditation Airway Clearance Techniques (ACT) Course: train the trainer and accreditation of</b>	14:00 - 14:00

	<b>twenty-one specialized international physiotherapists in Glasgow 2024</b>	
	Poster author: Brenda Button (Melbourne, Australia)	
P207	<b>Supporting equity in educational access: analysis of physiotherapy special interest group membership</b>	14:00 - 14:00
	Poster author: Adam Walsh (Liverpool, United Kingdom)	
P208	<b>Physiotherapists' experiences of using digital health technologies in adult cystic fibrosis care</b>	14:00 - 14:00
	Poster author: Lisa Morrison (Glasgow, United Kingdom)	
P209	<b>Relationship between viruses and pulmonary exacerbations in young children with cystic fibrosis</b>	14:00 - 14:00
	Poster author: Kim Van Hoorenbeeck (Edegem, Belgium)	
P210	<b>Chronic lung infection in mouse induced by oropharyngeal aspiration of <i>P. aeruginosa</i> PAO1 and TR66 agar beads embedded</b>	14:00 - 14:00
	Poster author: Gabriella Bergamini (Verona, Italy)	
P211	<b>Discriminating old from new: application of Fourier Transform Infrared Spectroscopy (FTIR) to the reappearance of <i>Pseudomonas aeruginosa</i> in patients with cystic fibrosis</b>	14:00 - 14:00
	Poster author: Martina Rossitto (Rome, Italy)	
P212	<b>Characteristics of anaerobic flora of the respiratory tract of children with cystic fibrosis</b>	14:00 - 14:00
	Poster author: Elena Kondratyeva (Moscow, Russian Federation)	
P213	<b>Monocentric retrospective study on oral antibiotic consumption in patients with cystic fibrosis between 2018-2023</b>	14:00 - 14:00
	Poster author: J. Till Othmer (Berlin, Germany)	
P214	<b>Microbial data overview of Latvian cystic fibrosis patients and first case of <i>Mycobacterium abscessus</i> and <i>Mycobacterium chimaera</i> co-infection</b>	14:00 - 14:00
	Poster author: Dita Gaidule-Logina (Riga, Latvia)	
P215	<b>Pilot implementation of self-obtained respiratory cultures at home for patients with cystic fibrosis</b>	14:00 - 14:00
	Poster author: Christopher Siracusa (Cincinnati, United States)	
P216	<b>Airway sampling in adult pwCF. Patients' self-reported practices, perceptions and preferences of airway clearance and different airway sampling techniques post elexacaftor/tezacaftor/ivacaftor (ETI)</b>	14:00 - 14:00
	Poster author: Kevin F Deasy (Cork, Ireland)	
P217	<b>Exploring different sampling techniques to best characterise the airway microbiota in pwCF on elexacaftor/tezacaftor/ivacaftor (ETI) and prior <i>Pseudomonas aeruginosa</i> (PA) colonisation</b>	14:00 - 14:00
	Poster author: Kevin F Deasy (Cork, Ireland)	
P218	<b>Reshaping but not restoring: The impact of elexacaftor/tezacaftor/ivacaftor on the lung microbiome and interactome in people with cystic fibrosis and advanced lung disease</b>	14:00 - 14:00
	Poster author: Francesca Lucca (Verona, Italy)	
P219	<b>Biofilm formation and biofilm-forming gene in <i>Pseudomonas aeruginosa</i> isolated from patients with cystic fibrosis</b>	14:00 - 14:00
	Poster author: Zulfirya Sadeeva (Moscow, Russian Federation)	
P220	<b>The impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on airway infections in people with cystic fibrosis (pwCF)</b>	14:00 - 14:00
	Poster author: Beatrice Silvia Orena (Milan, Italy)	

P221	<b>Investigation of antimicrobial effects of superhydrophilic and superhydrophobic copper surfaces in high-touch areas of hospitals</b>	14:00 - 14:00
<i>Poster author:</i> Marina Chernukha (Moscow, Russian Federation)		
P222	<b>Monitoring of chronic lung infection caused by <i>Staphylococcus aureus</i> in patients with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Olga S. Medvedeva (Moscow, Russian Federation)		
P223	<b>The role of horizontal Gene transfer in the development of resistance in <i>Achromobacter ruhlandii</i></b>	14:00 - 14:00
<i>Poster author:</i> Lusine Avetisyan (Moscow, Russian Federation)		
P224	<b>Promoting uniformity in microbiological sample collection in Italian cystic fibrosis centers: investigating practices and introducing a standardization poster</b>	14:00 - 14:00
<i>Poster author:</i> Marica Bovio (Genoa, Italy)		
P225	<b>Clinical impact of chronic multidrug resistant <i>Pseudomonas aeruginosa</i> infection in children with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Burcu Capraz Yavuz (Ankara, Turkey)		
P226	<b>Impact of modulator therapy on the chronic colonization of lower respiratory tract pathogens in children: data from the cystic fibrosis registry of Turkey</b>	14:00 - 14:00
<i>Poster author:</i> Meltem Akgül Erdal (Ankara, Turkey)		
P227	<b>The impact of CFTR modulator therapy on lower airway microbiota in people with cystic fibrosis: A systematic review and meta-analysis</b>	14:00 - 14:00
<i>Poster author:</i> Klementina Ocskay (Budapest, Hungary)		
P228	<b>13 years of fungal isolation in an adult cystic fibrosis centre in Argentina</b>	14:00 - 14:00
<i>Poster author:</i> Ezequiel Baran (La Plata, Argentina)		
P229	<b>Impact of elexacaftor/tezacaftor/ivacaftor on fungal dynamic colonization and outcomes of allergic bronchopulmonary aspergillosis children and adolescents with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Isabelle Sermet-Gaudelus (Paris, France)		
P230	<b>Bugs in the system: ECFS clinical trials network survey of microbiology sites</b>	14:00 - 14:00
<i>Poster author:</i> Kate Hill (Belfast, United Kingdom)		
P231	<b><i>Nocardia wallacei</i> and <i>Aspergillus Fumigatus</i> complex, an exacerbating combination</b>	14:00 - 14:00
<i>Poster author:</i> Ana Morales Tirado (Madrid, Spain)		
P232	<b>The United Kingdom Cystic Fibrosis Infection Biorepository (UKCFIB): supporting research and development efforts towards new antimicrobials</b>	14:00 - 14:00
<i>Poster author:</i> Amie Micallef (London, United Kingdom)		
P233	<b>Synergy between the repurposed drug glatiramer acetate and tobramycin extends to an expanded panel of <i>Pseudomonas aeruginosa</i> from people with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Rachel F. Rollo (London, United Kingdom)		
P234	<b>The repurposed multiple sclerosis drug, glatiramer acetate, compromises membrane integrity of pathogenic bacteria and enhances antibiotic effectiveness</b>	14:00 - 14:00
<i>Poster author:</i> Anaïs Daly-Gourdialsing (London, United Kingdom)		
P235	<b>Detection of mucoid hyper-biofilm forming <i>Staphylococcus aureus</i> isolates from respiratory specimen of people with cystic fibrosis on Congo Red agar</b>	14:00 - 14:00

Poster author: Maïke I. Diehl (Muenster, Germany)

P236 **Are postal sputum samples a valid clinical and research tool for use in cystic fibrosis?** 14:00 - 14:00

Poster author: David Green (Liverpool, United Kingdom)

P237 **Prevalence and clinical impact of *Staphylococcus aureus* small colony variant in people with cystic fibrosis followed at the Tuscan Regional Reference Centre** 14:00 - 14:00

Poster author: Vito Terlizzi (Firenze, Italy)

P238 ***Escherichia coli* in chronic infection of patients with cystic fibrosis. New opportunities for eradication** 14:00 - 14:00

Poster author: Olga Voronina (Moscow, Russian Federation)

P241 **The clinical impact of *M. abscessus* complex pulmonary disease in patients with cystic fibrosis: a secondary analysis of the IRENE registry** 14:00 - 14:00

Poster author: Gianmarco Putti

P242 **Clonal persistence of *Pseudomonas aeruginosa* after treatment with highly effective modulators: insights into adaptive responses in human airways** 14:00 - 14:00

Poster author: Maria Pals Bendixen (Copenhagen, Denmark)

P243 **New *Pseudomonas aeruginosa* isolates in adult and paediatric patients with CF in North West UK - Evaluation of treatment, eradication rate and strain typing** 14:00 - 14:00

Poster author: Aditi Sinha (Manchester, United Kingdom)

P244 **Induced colistin resistance in *Pseudomonas aeruginosa* biofilms is blocked by ArnT inhibitors** 14:00 - 14:00

Poster author: Martina Cristofori (Rome, Italy)

P245 **Phenotypic evolution of virulence factors of two *Pseudomonas aeruginosa* coexisting clones during cystic fibrosis airways infection associated to negative prognosis** 14:00 - 14:00

Poster author: Irene Paris (Rome, Italy)

P246 **How successful is the implementation of new national guidelines for microbiological surveillance of respiratory infections?** 14:00 - 14:00

Poster author: Veronika Skalicka (Prague, Czech Republic)

P247 **Assessment of symptom duration and treatment response to oral amoxicillin/clavulanic acid (co-amoxiclav) in paediatric cystic fibrosis exacerbations after the Introduction of Precision Medication (PM)** 14:00 - 14:00

Poster author: Kathryn Braisdell (Sheffield, United Kingdom)

P248 **The role of fungal infection with *Aspergillus fumigatus* in the etiology of bronchopulmonary infection in children with cystic fibrosis and other chronic lung diseases** 14:00 - 14:00

Poster author: Cristina Tomacinschii (Chisinau, Moldova)

P249 ***Aspergillus fumigatus* prevalence in Georgian paediatric cystic fibrosis patients** 14:00 - 14:00

Poster author: Nino Vardosanidze (Tbilisi, Georgia)

P250 **Cough swab vs sputum? A comparison in real world paediatric cystic fibrosis (CF) Clinics** 14:00 - 14:00

Poster author: Claire Lord (Middlesbrough, United Kingdom)

P252 **Prevalence of infections and assessment of lung function in cystic fibrosis paediatric patients treated with elexacaftor/tezacaftor/ivacaftor: a retrospective experience** 14:00 - 14:00

Poster author: Nicola Perrotta (Rome, Italy)



P253	<b><i>In vitro</i> restoration of colistin susceptibility by ivacaftor with non-replication in a murine pneumonia model</b>	14:00 - 14:00
<i>Poster author:</i> Claus Moser (Copenhagen, Denmark)		
P254	<b>De-escalation of inhaled antibiotics for chronic <i>Pseudomonas aeruginosa</i> infection in cystic fibrosis lungs</b>	14:00 - 14:00
<i>Poster author:</i> Lucy Thompson (Bristol, United Kingdom)		
P255	<b>Localised chronic <i>Pseudomonas aeruginosa</i> lung infection in cystic fibrosis rats</b>	14:00 - 14:00
<i>Poster author:</i> Nicole Reyne (Adelaide, Australia)		
P256	<b>The role of respiratory viruses in pulmonary exacerbations and their interactions with the airway microbiome and immune response in children with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Joke Bastiaenssen (Antwerp, Belgium)		
P257	<b>The assessment of <i>P. aeruginosa</i> virulence genes in models reflecting the CF lung</b>	14:00 - 14:00
<i>Poster author:</i> Tegan Hibbert (Liverpool, United Kingdom)		
P258	<b>Eradication of <i>Burkholderia cepacia</i> complex with off label inhaled antibiotics</b>	14:00 - 14:00
<i>Poster author:</i> Ezequiel Baran (La Plata, Argentina)		
 <i>Workshop</i> 15:00 - 16:30		
<b>WS01 - WS01 - The power of real-world data to solve long term problems</b>		
<i>Moderator:</i> Gwyneth Davies (London, United Kingdom)		
<i>Moderator:</i> Tavs Qvist (Copenhagen, Denmark)		
WS01.01	<b>Predicting future pulmonary exacerbation (PE<sub>x</sub>) rates for cystic fibrosis (CF) clinical trials</b>	15:00 - 15:15
<i>Oral abstract presenter:</i> Donald VanDevanter (Cleveland, United States)		
WS01.02	<b>Use of medications for sleep, depression, and anxiety in people with cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor</b>	15:15 - 15:30
<i>Oral abstract presenter:</i> Camilla Bjørn Jensen (Frederiksberg, Denmark)		
WS01.03	<b>Factors associated with persistent <i>Pseudomonas aeruginosa</i> infection following elexacaftor/tezacaftor/ivacaftor treatment: insights from the European Cystic Fibrosis Society Patient Registry</b>	15:30 - 15:45
<i>Oral abstract presenter:</i> Mordechai Pollak (Petah Tikvah, Israel)		
WS01.04	<b>Elexacaftor/tezacaftor/ivacaftor reduces the risk of lung transplantation or death among people with advanced CF lung disease in the United States</b>	15:45 - 16:00
<i>Oral abstract presenter:</i> Elizabeth Cromwell (Bethesda, United States)		
WS01.05	<b>Time to reimbursement for elexacaftor/tezacaftor/ivacaftor across countries in the ECFS patient registry</b>	16:00 - 16:15
<i>Oral abstract presenter:</i> Benedict Young (London, United Kingdom)		
WS01.06	<b>When is best to start treatment with tobramycin in people with chronic <i>Pseudomonas aeruginosa</i> infection? An emulated trial using the UK CF Registry</b>	16:15 - 16:30
<i>Oral abstract presenter:</i> Emily Granger (London, United Kingdom)		

*Workshop*

15:00 - 16:30

**WS02 - WS02 - Mental health and care in the post CFTR modulator era - broaden the view***Moderator:* Sarah Carroll (Dublin, Ireland)*Moderator:* Urszula Borawska-Kowalczyk (Warsaw, Poland)

- |         |   |               |
|---------|---|---------------|
| WS02.01 | <b>Provider perspectives related to the care of sexual and gender minority people living with cystic fibrosis in the United States and Canada</b> | 15:00 - 15:15 |
|---------|---|---------------|

*Oral abstract presenter:* Traci Kazmerski (Pittsburgh, United States)

- |         |  |               |
|---------|--|---------------|
| WS02.02 | <b>Experience and needs of children who have a parent with cystic fibrosis</b> | 15:15 - 15:30 |
|---------|--|---------------|

*Oral abstract presenter:* Anne Jacob (Boulogne-Billancourt, France)

- |         |   |               |
|---------|---|---------------|
| WS02.03 | <b>Cracking the code of CF: empowering children with cystic fibrosis through peer-created resources</b> | 15:30 - 15:45 |
|---------|---|---------------|

*Oral abstract presenter:* Eleanor Lee Mindel (London, United Kingdom)

- |         |  |               |
|---------|--|---------------|
| WS02.04 | <b>Perspectives on inhaled therapy in the post-CFTR modulator era: a survey of adults with cystic fibrosis</b> | 15:45 - 16:00 |
|---------|--|---------------|

*Oral abstract presenter:* Robert David Sandler (Sheffield, United Kingdom)

- |         |  |               |
|---------|--|---------------|
| WS02.05 | <b>The effect of sleep on the quality of life of children with cystic fibrosis</b> | 16:00 - 16:15 |
|---------|--|---------------|

*Oral abstract presenter:* Dilber Ademhan Tural (Ankara, Turkey)

- |         |  |               |
|---------|--|---------------|
| WS02.06 | <b>Elexacaftor/tezacaftor/ivacaftor pharmacokinetics and occurrence of behavioural disorders in children aged 2 to 5 years old</b> | 16:15 - 16:30 |
|---------|--|---------------|

*Oral abstract presenter:* Ngoc Hoa Truong (Paris, France)*Workshop*

15:00 - 16:30

**WS03 - WS03 - Airway clearance and exercise: practical physiotherapy approaches***Moderator:* Riccardo Guarise (Verona, Italy)*Moderator:* Marlies Wagner (Graz, Austria)

- |         |   |               |
|---------|---|---------------|
| WS03.02 | <b>High-intensity interval training and moderate-intensity continuous training are equivalent in improving exercise capacity at submaximal intensity in adults with cystic fibrosis</b> | 15:00 - 15:15 |
|---------|---|---------------|

*Oral abstract presenter:* Wolfgang Gruber (Kiel, Germany)

- |         |   |               |
|---------|---|---------------|
| WS03.03 | <b>Capturing a cough. Results of a pilot study to assess the utility of cough plates for microbiological surveillance in CF</b> | 15:15 - 15:30 |
|---------|---|---------------|

*Oral abstract presenter:* Catherine Fordyce (Manchester, United Kingdom)

- |         |  |               |
|---------|--|---------------|
| WS03.04 | <b>Impaired oxygen pulse during exercise following lung transplant in cystic fibrosis: a case series</b> | 15:30 - 15:45 |
|---------|--|---------------|

*Oral abstract presenter:* Owen Tomlinson (Exeter, United Kingdom)

- |         |  |               |
|---------|--|---------------|
| WS03.05 | <b>What factors influence heart rate reserve in evaluating and prescribing exercise intensity for children and young people with CF?</b> | 15:45 - 16:00 |
|---------|--|---------------|

*Oral abstract presenter:* William Shirras (London, United Kingdom)

- |         |  |               |
|---------|--|---------------|
| WS03.06 | <b>A novel use of electrical impedance tomography in children with cystic fibrosis</b> | 16:00 - 16:15 |
|---------|--|---------------|

*Oral abstract presenter:* Julie Depiazzi (Perth, Australia)

*Workshop*

15:00 - 16:30

**WS04 - WS04 - From dysbiosis to dysfunction: gastrointestinal and metabolic complications to cystic fibrosis***Moderator:* Frank Bodewes (Groningen, Netherlands)*Moderator:* Chris Smith (Brighton, United Kingdom)

- |         |   |               |
|---------|---|---------------|
| WS04.01 | <b>Faecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor/tezacaftor/ivacaftor: findings from the PROMISE study</b> | 15:00 - 15:15 |
|---------|---|---------------|

*Oral abstract presenter:* Jennifer T Duong (Oakland, United States)

- |         |  |               |
|---------|--|---------------|
| WS04.02 | <b>Gut microbiota-metabolome relationships across CFTR modulator usage: preliminary findings from the GRAMPUS-CF study</b> | 15:15 - 15:30 |
|---------|--|---------------|

*Oral abstract presenter:* Ryan Marsh (Newcastle upon Tyne, United Kingdom)

- |         |  |               |
|---------|--|---------------|
| WS04.03 | <b>Stool and symptom testing in colorectal evaluation for neoplasia in cystic fibrosis (SCREEN-CF)</b> | 15:30 - 15:45 |
|---------|--|---------------|

*Oral abstract presenter:* Nicole Taylor (Sydney, Australia)

- |         |  |               |
|---------|--|---------------|
| WS04.05 | <b>Faecal colorectal cancer-associated toxins in adults with cystic fibrosis: preliminary analysis</b> | 15:45 - 16:00 |
|---------|--|---------------|

*Oral abstract presenter:* Laura R. Caley (Leeds, United Kingdom)

- |         |  |               |
|---------|--|---------------|
| WS04.06 | <b>Observations on CFTR modulators and pancreatic function in a clinical trial of ANG003, a novel pancreatic enzyme replacement therapy in people with cystic fibrosis</b> | 16:00 - 16:15 |
|---------|--|---------------|

*Oral abstract presenter:* Steven D. Freedman (Boston, United States)*Workshop*

15:00 - 16:30

**WS05 - WS05 - Nucleic acid based therapies: progress and potential***Moderator:* Stephen Hart (London, United Kingdom)*Moderator:* Eitan Kerem (Jerusalem, Israel)

- |         |  |               |
|---------|--|---------------|
| WS05.01 | <b>Lipid nanoparticles and vesicles delivery tools to deliver mRNA and ribonucleoprotein to the lungs for the development of genome editing in cystic fibrosis</b> | 15:00 - 15:15 |
|---------|--|---------------|

*Oral abstract presenter:* Giulia Maule (Trento, TN, Italy)

- |         |   |               |
|---------|---|---------------|
| WS05.02 | <b>CFTR mRNA delivery with a revolutionary non-LNP nanoemulsion formulation to differentiated primary human airway epithelium and airway organoid</b> | 15:15 - 15:30 |
|---------|---|---------------|

*Oral abstract presenter:* Kazuhiro Ito (London, United Kingdom)

- |         |   |               |
|---------|---|---------------|
| WS05.03 | <b>Single administration of a lipid nanoparticle encapsulating HA-tagged CFTR mRNA to non-human primate lung results in expression of mRNA and protein in airway epithelium</b> | 15:30 - 15:45 |
|---------|---|---------------|

*Oral abstract presenter:* Joseph Chen (Menlo Park, CA, United States)

- |         |   |               |
|---------|---|---------------|
| WS05.04 | <b>Comparison of preclinical and preliminary clinical safety profile of SPL84, an ASO for treatment of CF patients carrying the 3849 +10 Kb C -&gt; T mutation, supporting an ongoing Phase 2 study</b> | 15:45 - 16:00 |
|---------|---|---------------|

*Oral abstract presenter:* Lital Friedman (Jerusalem, Israel)

- |         |  |               |
|---------|--|---------------|
| WS05.05 | <b>SPL5AC, MUC5AC Lowering ASO for cystic fibrosis and other mucobstructive diseases</b> | 16:00 - 16:15 |
|---------|--|---------------|

*Oral abstract presenter:* Efrat Ozeri-Galai (Jerusalem, Israel)

- |         |   |               |
|---------|---|---------------|
| WS05.06 | <b>Design of an adenine base editor for temporospatial control of editing</b> | 16:15 - 16:30 |
|---------|---|---------------|

*Oral abstract presenter:* Carlos M Farinha (Lisboa, Portugal)

*ECFS Tomorrow Lounge Session*

16:30 - 17:00

**Speaker Corner***Speaker:* Andrew Jones (Manchester, United Kingdom)*Speaker:* Carsten Schwarz (Potsdam, Germany)*Speaker:* Peder Berg (Aarhus, Denmark)*Speaker:* Steven D. Freedman (Boston, United States)*Speaker:* Tanja Gonska (Toronto, Canada)*Speaker:* Donald Urquhart (Edinburgh, United Kingdom)*Coffee Break*

16:30 - 17:00

**Coffee Break***Workshop*

17:00 - 18:30

**WS06 - WS06 - The new frontier: pregnancy in the CFTR modulator era***Moderator:* Carmen Luna-Paredes (MADRID, Spain)*Moderator:* Imogen Felton (London, United Kingdom)

WS06.01	<b>Prenatal CFTR Modulator Exposure: a Review of the European and U.S. Experience</b>	17:00 - 17:15
---------	---	---------------

*Oral abstract presenter:* Sylvia Szentpetery (Charleston, United States)

WS06.02	<b>Pharmacology of fetal therapy in cystic fibrosis. Report from the MODUL-CF study</b>	17:15 - 17:30
---------	---	---------------

*Oral abstract presenter:* Isabelle Sermet-Gaudelus (Paris, France)

WS06.03	<b>Towards consensus guidelines: an international survey of follow-up practices for babies exposed to CFTR modulators (CFTRm) in utero and/or via lactation</b>	17:30 - 17:45
---------	---	---------------

*Oral abstract presenter:* Idan Bokobza (London, United Kingdom)

WS06.04	<b>Cystic fibrosis and pregnancy: the impact of modulator therapy</b>	17:45 - 18:00
---------	---	---------------

*Oral abstract presenter:* David Green (Liverpool, United Kingdom)

WS06.05	<b>Fetal drug exposure after maternally administered elexacaftor/tezacaftor/ivacaftor in a rat model</b>	18:00 - 18:15
---------	--	---------------

*Oral abstract presenter:* Elena Schneider-Futschik (Melbourne, Australia)

WS06.06	<b>Exploring experiences of people with cystic fibrosis who have become mothers in the CFTR modulator era</b>	18:15 - 18:30
---------	---	---------------

*Oral abstract presenter:* Rebecca Dobra (London, United Kingdom)*Workshop*

17:00 - 18:30

**WS07 - WS07 - Novel monitoring of cystic fibrosis lung disease: imaging, lung function and other biomarkers***Moderator:* Hettie Janssens (Rotterdam, Netherlands)*Moderator:* Francesco Blasi (Milan, Italy)

WS07.01	<b>'Silent' lung disease progression in people receiving elexacaftor/tezacaftor/ivacaftor (ETI) therapy revealed by Oxygen Enhanced-MRI (OE-MRI) and Multiple breath washout with Short extension (MBW<sub>ShX</sub>)</b>	17:00 - 17:15
---------	---	---------------

*Oral abstract presenter:* Christopher Short (London, United Kingdom)

WS07.02	<b>Investigating imaging biomarkers in cystic fibrosis preschoolers using manual and Artificial intelligence-based algorithms</b>	17:15 - 17:30
---------	---	---------------

*Oral abstract presenter:* Pranali Raut (Rotterdam, Netherlands)

WS07.03	<b>Expiratory lung proton magnetic resonance imaging is a simple sensitive method to detect gas trapping in cystic fibrosis?</b>	17:30 - 17:45
---------	--	---------------

Oral abstract presenter: Amy V Simmons (Sheffield, United Kingdom)

WS07.04      **Baseline variability in percent predicted forced expiratory volume in one second predicts short-term lung function response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis**      17:45 - 18:00

Oral abstract presenter: Harjot Bhandol (Vancouver, Canada)

WS07.05      **Indirect evaluation of lung condition by means of low field nuclear magnetic resonance following chest physiotherapy or modulator drug administration in cystic fibrosis patients**      18:00 - 18:15

Oral abstract presenter: Michela Abrami (Trieste, Italy)

WS07.06      **Early change in forced vital capacity as a determinant of outcome in pulmonary exacerbations of cystic fibrosis**      18:15 - 18:30

Oral abstract presenter: Oliver J. McElvaney (Seattle, United States)

#### Workshop

17:00 - 18:30

#### **WS08 - WS08 - Microbial shifts: the impact of ETI on infection, and the lung microbiome**

Moderator: Wendy Unger (Rotterdam, Netherlands)

Moderator: Catherine Armbruster (Pittsburgh, United States)

WS08.02      **Specific *Pseudomonas aeruginosa* IgG levels before and after elexacaftor/tezacaftor/ivacaftor treatment**      17:00 - 17:15

Oral abstract presenter: Thomas Bryrup (Copenhagen, Denmark)

WS08.03      **Remodelling of cystic fibrosis respiratory microbiota in response to extended elexacaftor/tezacaftor/ivacaftor therapy**      17:15 - 17:30

Oral abstract presenter: Helen Gavillet (Newcastle Upon Tyne, United Kingdom)

WS08.04      **Analyzing the impact of elexacaftor/tezacaftor/ivacaftor treatment and *Pseudomonas* infection on gene expression in cystic fibrosis primary bronchial epithelial cultures**      17:30 - 17:45

Oral abstract presenter: Ashlesha Chaubal (Chapel Hill, United States)

WS08.05      **Multi-omics insights into *Pseudomonas aeruginosa*'s adaptation to elexacaftor/tezacaftor/ivacaftor therapy**      17:45 - 18:00

Oral abstract presenter: Laura Veschetti (Milano, Italy)

WS08.06      **Integrative computational analysis of longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum microbiome and proteome in patients with cystic fibrosis**      18:00 - 18:15

Oral abstract presenter: Laura Schaupp (Berlin, Germany)

WS08.01      **Reshaping but not restoring: The impact of elexacaftor/tezacaftor/ivacaftor on the lung microbiome and interactome in people with cystic fibrosis and advanced lung disease**      18:15 - 18:30

Oral abstract presenter: Andrea Gramegna (Milan, Italy)

#### Workshop

17:00 - 18:30

#### **WS09 - WS09 - CFTR-expressing epithelia in health and disease**

Moderator: Luis Galletta (Pozzuoli, Italy)

Moderator: Carlos M Farinha (Lisboa, Portugal)

WS09.01      **CFTR activity in nasal epithelia from subjects with different genotypes**      17:00 - 17:15

Oral abstract presenter: Valeria Capurro (Genoa, Italy)

WS09.02      **Intestinal current measurement detects age-dependent differences in CFTR function in rectal epithelium**      17:15 - 17:30

Oral abstract presenter: Simon Y. Graeber (Berlin, Germany)

WS09.03	<b>SLC26A9-mediated chloride transport is important for mucociliary clearance by healthy and cystic fibrosis airway epithelium</b>	17:30 - 17:45
<i>Oral abstract presenter:</i> Anita Balazs (Berlin, Germany)		
WS09.04	<b>Beyond chloride: a multi-omic integration analysis to identify the effects of elexacaftor/tezacaftor/ivacaftor in F508del primary airway epithelial cultures</b>	17:45 - 18:00
<i>Oral abstract presenter:</i> Mairead Kelly-Aubert (Paris, France)		
WS09.05	<b>Potential antimicrobial effects induced in cultured human bronchial epithelia by IL-17/TNF-alpha</b>	18:00 - 18:15
<i>Oral abstract presenter:</i> Daniela Guidone (Pozzuoli (Naples), Italy)		
WS09.06	<b>Investigation of HE4 expression in relation to epithelial mesenchymal transition in cystic fibrosis epithelial cells</b>	18:15 - 18:30
<i>Oral abstract presenter:</i> Marianna Pócsi (Debrecen, Hungary)		

*Special Symposium*

17:00 - 18:30

**Best of Journal of Cystic Fibrosis, Lancet Respiratory Medicine and European Respiratory Journal***Moderator:* Patrick Flume (Charleston, United States)*Moderator:* Emma Grainger (London, United Kingdom)*Moderator:* Marcus A. Mall (Berlin, Germany)**Introduction** 17:00 - 17:05**Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment** 17:05 - 17:30*Speaker:* Edith Zemanick (Aurora, United States)*Discussant:* Patrick Flume (Charleston, United States)**Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials** 17:30 - 17:55*Speaker:* Alexander Horsley (Manchester, United Kingdom)*Discussant:* Kevin Southern (Liverpool, United Kingdom)**Relationship between theratyping in nasal epithelial cells and clinical outcomes in people with cystic fibrosis** 17:55 - 18:20*Speaker:* Felix Ratjen (Toronto, Canada)*Discussant:* Isabelle Sermet-Gaudelus (Paris, France)**Discussion - Hot Topics in Publishing** 18:20 - 18:30*ECFS Tomorrow Lounge Session*

17:00 - 18:00

**I've got a gut feeling this is going to be important: the brain-gut axis in CF care***Moderator:* Rachel Massey-Chase (London, United Kingdom)*Moderator:* Kerry-Lee Watson (United Kingdom)

**Friday, 06. June 2025***Meet the Experts*

07:45 - 08:45

**MTE 4 - MTE 4 - To test or not to test - the impact of antibiotic susceptibility testing on clinical outcomes***Expert:* Helle Krogh Johansen (Copenhagen, Denmark)*Expert:* Pavel Drevinec (Prague, Czech Republic)*Meet the Experts*

07:45 - 08:45

**MTE 5 - MTE 5 - Pharmacology and psychological side effects of modulator therapy***Expert:* Anna M. Georgiopoulos (Boston, United States)*Expert:* Isabelle Sermet-Gaudelus (Paris, France)*Meet the Experts*

07:45 - 08:45

**MTE 6 - MTE 6 - How to better diagnose a CFTR-RD with the wide range of tools available (from genetics to functional and clinical explorations)***Expert:* Nicholas Simmonds (London, United Kingdom)*Expert:* Elke De Wachter (Brussels, Belgium)*Industry Sessions*

08:00 - 08:45

**Industry Symposium***Symposium*

09:00 - 10:30

**S11 - Symposium 11 - Imaging in cystic fibrosis, my view!***Moderator:* Paul McNally (Dublin, Ireland)*Moderator:* Olaf Sommerburg (Heidelberg, Germany)**Lung MR imaging, now or never?**

09:00 - 09:22

*Speaker:* Mark O. Wielpütz (Greifswald, Germany)**CT-scans for evaluation of cystic fibrosis lung disease, now and forever?**

09:22 - 09:44

*Speaker:* Daan Caudri (Rotterdam, Netherlands)**The decline of the chest X-ray and rise of ultrasound in chest imaging in cystic fibrosis?**

09:44 - 10:06

*Speaker:* Shum mickael (Creteil, France)**Disparities and correlations between radiological imaging and physiological assessments in cystic fibrosis lung disease**

10:06 - 10:30

*Speaker:* Sarath Ranganathan (Melbourne, Australia)*Symposium*

09:00 - 10:30

**S12 - Symposium 12 - Every breath you take***Moderator:* Olaf Eickmeier (Frankfurt, Germany)*Moderator:* Lisa Morrison (Glasgow, United Kingdom)**Climate, environment and the pwCF**

09:00 - 09:22

*Speaker:* Scott Bell (Southport, Australia)**My lung function is good, but my breathing is not!**

09:22 - 09:44

*Speaker:* Eva Polverino (Barcelona, Spain)

<b>Wind of change for rehabilitation</b>	09:44 - 10:06
<i>Speaker:</i> Thomas Radtke (Zurich, Switzerland)	
<b>Sleep, the forgotten third of cystic fibrosis</b>	10:06 - 10:30
<i>Speaker:</i> Elizabeth Tullis (Toronto, Canada)	
<i>Symposium</i> 09:00 - 10:30	
<b>S13 - Symposium 13 - Nutrition throughout life</b>	
<i>Moderator:</i> Monika Mielus (Warsaw, Poland)	
<i>Moderator:</i> Joanna Snowball (Oxford, United Kingdom)	
<b>Nutrition in the first 1000 critical days and beyond - opportunities and challenges</b>	09:00 - 09:22
<i>Speaker:</i> Catherine McDonald (Salt Lake City, United States)	
<b>Disordered eating - is it an emerging issue in cystic fibrosis?</b>	09:22 - 09:44
<i>Speaker:</i> Edwina Landau (Petah Tikva, Israel)	
<b>Feeding the fetus and the mother - cystic fibrosis nutrition in pregnancy</b>	09:44 - 10:06
<i>Speaker:</i> Sarah Collins (London, United Kingdom)	
<b>Increased cancer risk in people with cystic fibrosis - is there a specific diet?</b>	10:06 - 10:30
<i>Speaker:</i> Daina Kalnins (Toronto, Canada)	
<i>Symposium</i> 09:00 - 10:30	
<b>S14 - Symposium 14 - Navigating challenges in gene therapy</b>	
<i>Moderator:</i> Marianne S. Carlon (Leuven, Belgium)	
<i>Moderator:</i> Ewart Kuijk (Utrecht, Netherlands)	
<b>LNP vehicles to deliver large gene editing payloads to the cystic fibrosis lung</b>	09:00 - 09:22
<i>Speaker:</i> Anna Cereseto (Trento, Italy)	
<b>Targeted integration of CFTR cDNA as a pan-mutational gene therapy</b>	09:22 - 09:44
<i>Speaker:</i> Sriram Vaidyanathan (Columbus, United States)	
<b>Endosomal escape strategies to enhance LNP-based gene delivery</b>	09:44 - 10:06
<i>Speaker:</i> Stephen Hart (London, United Kingdom)	
<b>Insights from single cell transcriptomics to shed a light on target cells for CF gene therapies, in light of airway epithelial regeneration in the CF lung</b>	10:06 - 10:30
<i>Speaker:</i> Laure-Emmanuelle Zaragosi (Valbonne Sophia-Antipolis, France)	
<i>Symposium</i> 09:00 - 10:30	
<b>S15 - Symposium 15 - Closing the gap: the intersection of epidemiology, data harmonisation, and access to treatments in cystic fibrosis</b>	
<i>Moderator:</i> Lutz Naehrlich (Giessen, Germany)	
<i>Moderator:</i> Marco Zampoli (Cape Town, South Africa)	
<b>United in data: overcoming global registry disparities</b>	09:00 - 09:22
<i>Speaker:</i> Anne Stephenson (Toronto, Canada)	
<b>From bench to bedside: the role of registries in expanding the label for CFTR modulators</b>	09:22 - 09:44
<i>Speaker:</i> Pierre-Régis Burgel (Paris, France)	



<b>Global health insights: CFTR modulator access</b>	09:44 - 10:06
<i>Speaker:</i> Jonathan Guo (London, United Kingdom)	
<b>Twinning project: improving cystic fibrosis care throughout Europe and the role of data</b>	10:06 - 10:30
<i>Speaker:</i> Pavel Drevinek (Prague, Czech Republic)	
<i>ECFS Tomorrow Lounge Session</i> 09:00 - 10:00	
<b>Supporting adherence - the pharmacists' perspective</b>	
<i>Moderator:</i> Carina M.E. Hansen (Groningen, Netherlands)	
<i>Moderator:</i> Elena Schneider-Futschik (Melbourne, Australia)	
<i>ECFS Tomorrow Lounge Session</i> 10:30 - 11:00	
<b>Speaker Corner</b>	
<i>Speaker:</i> Sarath Ranganathan (Melbourne, Australia)	
<i>Speaker:</i> Scott Bell (Southport, Australia)	
<i>Speaker:</i> Daina Kalnins (Toronto, Canada)	
<i>Speaker:</i> Anna Cereseto (Trento, Italy)	
<i>Speaker:</i> Anne Stephenson (Toronto, Canada)	
<i>Coffee Break</i> 10:30 - 11:00	
<b>Coffee Break</b>	
<i>Symposium</i> 11:00 - 12:30	
<b>S16 - Symposium 16 - Smart monitoring for trials and clinical care</b>	
<i>Moderator:</i> Philippe Reix (Lyon, France)	
<i>Moderator:</i> Anna-Maria Dittrich (Hanover, Germany)	
<b>Monitoring exercise and lung health</b>	11:00 - 11:22
<i>Speaker:</i> Stephanie Thee (Berlin, Germany)	
<b>Asking questions: doctors or avatars?</b>	11:22 - 11:44
<i>Speaker:</i> Trudy Havermans (Leuven, Belgium)	
<b>Recording: Monitoring bowel symptoms</b>	11:44 - 12:06
<i>Speaker:</i> Rebecca J. Calthorpe (Nottingham, United Kingdom)	
<b>Monitoring patient perspectives</b>	12:06 - 12:28
<i>Speaker:</i> Danya Muilwijk (Utrecht, Netherlands)	
<i>Symposium</i> 11:00 - 12:30	
<b>S17 - Symposium 17 - Looking to the future</b>	
<i>Moderator:</i> Mirjam Stahl (Berlin, Germany)	
<i>Moderator:</i> Andrew Jones (Manchester, United Kingdom)	
<b>Projections for survival and future lung health in the era of CFTRm</b>	11:00 - 11:22
<i>Speaker:</i> Annalisa Orenti (Milan, Italy)	
<b>Starting CFTRm in early life</b>	11:22 - 11:44
<i>Speaker:</i> Paul McNally (Dublin, Ireland)	
<b>Global trends in cystic fibrosis and their impact on CF centres</b>	11:44 - 12:06
<i>Speaker:</i> Eitan Kerem (Jerusalem, Israel)	
<b>I need a holiday! Planning safe travel for pwCF</b>	12:06 - 12:30

Speaker: Heather Green (Manchester, United Kingdom)

#### Symposium

11:00 - 12:30

#### **S18 - Symposium 18 - Facing challenges in the post CFTRm era**

Moderator: Charlotte Dawson (London, United Kingdom)

Moderator: Dorien Holtslag (Maastricht, Netherlands)

##### **Adherence Post ETI - Are there new barriers we need to address?**

11:00 - 11:22

Speaker: Alexandra L. Quittner (Hollywood, United States)

##### **How much can social inequality in health impact outcomes for PwCF?**

11:22 - 11:44

Speaker: Maya Desai (Birmingham, United Kingdom)

##### **Preparing PwCF for aging- who should do this, when should it be introduced, what information should be provided?**

11:44 - 12:06

Speaker: Majda Oštir (Ljubljana, Slovenia)

##### **Supporting the CF Team throughout palliative care**

12:06 - 12:30

Speaker: Marica Bovio (Genova, Italy)

Speaker: Riccardo Ciprandi (Genoa, Italy)

#### Symposium

11:00 - 12:30

#### **S19 - Symposium 19 - Evolving tactics in *Pseudomonas aeruginosa* resistance development**

Moderator: Silvia Buroni (Pavia, Italy)

Moderator: Ruggero La Rosa (Copenhagen Ø, Denmark)

##### **Beyond the cycle - unveiling the consequences of repeated $\beta$ -Lactam exposure in cystic fibrosis**

11:00 - 11:22

Speaker: Claudia A Colque (Copenhagen, Denmark)

##### **Should we sequence every isolate - inference of antibiotic resistance through genetic determinants**

11:22 - 11:44

Speaker: Rasmus Lykke Marvig (Copenhagen, Denmark)

##### **Chronic infection dynamics - immune reactions to *pseudomonas aeruginosa***

11:44 - 12:06

Speaker: Elio Rossi (Milan, Italy)

##### **The next frontier - *pseudomonas aeruginosa*'s persistence in cystic fibrosis post-modulator therapy**

12:06 - 12:30

Speaker: Catherine Armbruster (Pittsburgh, United States)

#### Symposium

11:00 - 12:30

#### **S20 - Symposium 20 - Pushing the boundaries of newborn screening for cystic fibrosis**

Moderator: Vito Terlizzi (Firenze, Italy)

Moderator: Karen Raraigh (Baltimore, United States)

##### **The potential of genome sequencing to replace IRT as the initial test in the cystic fibrosis screening protocol**

11:00 - 11:22

Speaker: Caroline Raynal (Montpellier, France)

##### **Is it time to expand NBS for cystic fibrosis globally; yes**

11:22 - 11:40

Speaker: Marco Zampoli (Cape Town, South Africa)

##### **Is it time to expand NBS for cystic fibrosis globally; no**

11:40 - 11:58

Speaker: Kevin Southern (Liverpool, United Kingdom)

##### **Discussion**

11:58 - 12:08

**Newborn bloodspot screening for infants exposed to CFTR modulator therapy in utero**

12:08 - 12:30

*Speaker:* Jennifer L. Taylor-Cousar (Denver, United States)

*ECFS Tomorrow Lounge Session*

12:45 - 13:15

**Celebrate & Certify: A Relaxed Recognition Gathering for Our Award Winners (invite only)**

*Moderator:* Francesco Blasi (Milan, Italy)

*Moderator:* Carlo Castellani (Genoa, Italy)

*Moderator:* Nicoletta Pedemonte (Genoa, Italy)

*Industry Sessions*

13:00 - 14:00

**Industry Symposium**

*ePoster Session*

14:00 - 15:00

**EPS 5 - ePoster Session 5 - Physiotherapy in cystic fibrosis - Innovations and new insights**

*Leader:* Lisa Morrison (Glasgow, United Kingdom)

*Leader:* Helge Hebestreit (Würzburg, Germany)

EPS5.01	<b>Feasibility of mechanical insufflation-exsufflation usage as airway clearance technique in chest physiotherapy for women with cystic fibrosis during pregnancy - a retrospective single center study</b>	14:00 - 14:06
---------	---	---------------

*Oral ePoster presenter:* Irit Berry (Ramat Gan, Israel)

EPS5.02	<b>ImpACT4CF: involving children and young people in the development of a real-time airway clearance breath sensor and visual feedback platform to improve quality of airway clearance treatments</b>	14:06 - 14:12
---------	---	---------------

*Oral ePoster presenter:* Helen Douglas (London, United Kingdom)

EPS5.03	<b>Musculoskeletal health in an Australian paediatric cystic fibrosis population - is there a higher prevalence of joint hypermobility?</b>	14:12 - 14:18
---------	---	---------------

*Oral ePoster presenter:* Anne Sage (Nedlands, Australia)

EPS5.04	<b>"Another one?" - dealing with an increase in sputum induction referrals in a large adult UK cystic fibrosis (CF) Centre: A quality improvement initiative</b>	14:18 - 14:24
---------	--	---------------

*Oral ePoster presenter:* Afrasiab Ahmad (London, United Kingdom)

EPS5.05	<b>Clinical measures associated with aerobic capacity in adults with cystic fibrosis: a service evaluation</b>	14:24 - 14:30
---------	--	---------------

*Oral ePoster presenter:* Rachel McDowell (Bath, United Kingdom)

EPS5.06	<b>Seasonal variability in microbiological samples obtained via induced sputum in cystic fibrosis patients post CFTR modulator therapy</b>	14:30 - 14:36
---------	--	---------------

*Oral ePoster presenter:* Louisa Wallbridge (Sheffield, United Kingdom)

EPS5.07	<b>Frailty in an aging cystic fibrosis population</b>	14:36 - 14:42
---------	---	---------------

*Oral ePoster presenter:* Lisa Morrison (Glasgow, United Kingdom)

EPS5.08	<b>Increasing sputum sample frequency in children with cystic fibrosis without increasing hospital resources</b>	14:42 - 14:48
---------	--	---------------

*Oral ePoster presenter:* Crystal Bourke (Nedlands, Australia)

EPS5.09	<b>Influencing factors of physical activity in youth with cystic fibrosis: a socio-ecological approach</b>	14:48 - 14:54
---------	--	---------------

*Oral ePoster presenter:* Manon Kinaupenne (Ghent, Belgium)

EPS5.10	<b>Physical literacy in people with CF</b>	14:54 - 15:00
---------	--	---------------

*Oral ePoster presenter:* Marcella Burghard (Utrecht, Netherlands)

*ePoster Session*

14:00 - 15:00

**EPS 6 - ePoster Session 6 - Inflammation and patient outcomes in cystic fibrosis***Leader:* Andrea Gramegna (Milan, Italy)*Leader:* Jo Harrison (Melbourne, Australia)

EPS6.01                    **Increase in pulmonary exacerbations after fatherhood in cystic fibrosis**                    14:00 - 14:06

*Oral ePoster presenter:* Joel Reiter (Jerusalem, Israel)

EPS6.02                    **Pulmonary benefit of fortified breastmilk in children with cystic fibrosis in the first 6 years of life**                    14:06 - 14:12

*Oral ePoster presenter:* Philip Farrell (Madison, United States)

EPS6.03                    **Implications of adopting the race-neutral GLI 2022 in lung transplantation referral and clinical trial eligibility in adults with cystic fibrosis**                    14:12 - 14:18

*Oral ePoster presenter:* Aqeem Azam (Manchester, United Kingdom)

EPS6.04                    **Abridging the 22-item Sino-Nasal Outcome Test (SNOT-22) in people with cystic fibrosis to limit survey burden**                    14:18 - 14:24

*Oral ePoster presenter:* Daniel Beswick (Los Angeles, United States)

EPS6.05                    **The association of serum human epididymis protein 4 (HE4) and clinical, respiratory and laboratory findings in children with cystic fibrosis**                    14:24 - 14:30

*Oral ePoster presenter:* Meltem Akgül Erdal (Ankara, Turkey)

EPS6.06                    **Dampening lung inflammation in cystic fibrosis: switching towards resolution by acting on platelets**                    14:30 - 14:36

*Oral ePoster presenter:* Simona D'Orazio (Chieti, Italy)

EPS6.07                    **Correlation of responses in patient derived rectal organoids and clinical responses to modulators in people with CF homozygous for F508del-CFTR**                    14:36 - 14:42

*Oral ePoster presenter:* Noelia Rodriguez Mier (Leuven, Belgium)

EPS6.08                    **Targeting IL-17 signalling to modulate inflammation and enhance host defence in cystic fibrosis lung infections**                    14:42 - 14:48

*Oral ePoster presenter:* Chiara Ferrari (Milan, Italy)

EPS6.09                    **Association between elevated immunoglobulin G subclasses and positive *Pseudomonas aeruginosa* antibody levels in adult patients with and without highly effective modulator therapy**                    14:48 - 14:54

*Oral ePoster presenter:* Teresa Fuchs (Innsbruck, Austria)

EPS6.10                    **Spirometry grading and spirometry errors: a four-year review of home spirometry recording in adults with cystic fibrosis**                    14:54 - 15:00

*Oral ePoster presenter:* Aqeem Azam (Manchester, United Kingdom)*ePoster Session*

14:00 - 15:00

**EPS 7 - ePoster Session 7 - New therapies: from cell models to real-world evidence***Leader:* Dorota Sands (Warsaw, Poland)*Leader:* Kris De Boeck (Leuven, Belgium)

EPS7.01                    **Comparing elexacaftor and vanzacaftor: impact on CFTR functional rescue and protein maturation**                    14:00 - 14:06

*Oral ePoster presenter:* Gabrielle Langeveld (Toronto, Canada)

EPS7.02                    **Evaluation of rectal organoid responses to vanzacaftor/tezacaftor/ivacaftor in people with CF poorly responsive to elexacaftor/tezacaftor/ivacaftor modulator therapy**                    14:06 - 14:12

*Oral ePoster presenter:* Noelia Rodriguez Mier (Leuven, Belgium)

EPS7.03	<b>Assessing the impact of elexacaftor/tezacaftor/ivacaftor on workplace productivity and activity impairment in people living with cystic fibrosis in Canada as part of the CAN-IMPACT-CF study</b>	14:12 - 14:18
<i>Oral ePoster presenter:</i> Grace Gaeun Kim (Vancouver, Canada)		
EPS7.04	<b>Real world evaluation of the CF-ABLE score as a prognostic tool and clinical endpoint in cystic fibrosis</b>	14:18 - 14:24
<i>Oral ePoster presenter:</i> Oliver J. McElvaney (Seattle, United States)		
EPS7.05	<b>Therapeutic targeting of CFTR mutation-specific defects in cystic fibrosis patient-derived respiratory cells and organoids: advanced in vitro models and assays to guide personalized therapy</b>	14:24 - 14:30
<i>Oral ePoster presenter:</i> Adriana ERAMO (Rome, Italy)		
EPS7.06	<b>Mode of action of the FAIR therapeutics CFTR modulators nesolicaftor, posenacaftor and dirocaftor in <i>in vitro</i> and <i>in vivo</i> preclinical studies</b>	14:30 - 14:36
<i>Oral ePoster presenter:</i> Paraskevi Charitou (Oss, Netherlands)		
EPS7.07	<b>Safety assessment of the FAIR therapeutics CFTR modulators nesolicaftor, posenacaftor and dirocaftor in CF patients</b>	14:36 - 14:42
<i>Oral ePoster presenter:</i> Paraskevi Charitou (Oss, Netherlands)		
EPS7.09	<b>Verapamil limits inflammatory damage by reducing epithelial calcium activity in preclinical models of cystic fibrosis</b>	14:42 - 14:48
<i>Oral ePoster presenter:</i> Audrey Bernut (Montpellier, France)		
EPS7.10	<b>Evaluation of amniotic epithelial cells (hAECs) as a cell-based therapeutic approach for cystic fibrosis</b>	14:48 - 14:54
<i>Oral ePoster presenter:</i> Mariateresa Lena (Genova, Italy)		
<i>ePoster Session</i> 14:00 - 15:00		
<b>EPS 8 - ePoster Session 8 - Resistance is futile</b>		
<i>Leader:</i> Barbara Kahl (Münster, Germany)		
<i>Leader:</i> Tavs Qvist (Copenhagen, Denmark)		
EPS8.01	<b>Application of phage evolution to address the widespread phage-resistance of <i>Pseudomonas aeruginosa</i> strains isolated from people with cystic fibrosis</b>	14:00 - 14:06
<i>Oral ePoster presenter:</i> Alessandra Bosc (Milano, Italy)		
EPS8.02	<b>Hypoxia drives the adaptation to chronic infection in three different cystic fibrosis-associated pathogens (<i>Pseudomonas aeruginosa</i>, <i>Burkholderia cenocepacia</i> and <i>Mycobacterium abscessus</i>)</b>	14:06 - 14:12
<i>Oral ePoster presenter:</i> Ciaran Carey (Dublin, Ireland)		
EPS8.03	<b>Effects of elexacaftor/tezacaftor/ivacaftor on the nasal microbial metagenome in cystic fibrosis</b>	14:12 - 14:18
<i>Oral ePoster presenter:</i> Tom Lennart Hertramph (Hannover, Germany)		
EPS8.04	<b>Macrolide resistance through uL4 and uL22 ribosomal mutations in <i>Pseudomonas aeruginosa</i></b>	14:18 - 14:24
<i>Oral ePoster presenter:</i> Ruggero La Rosa (Copenhagen Ø, Denmark)		
EPS8.05	<b>Investigating the variability in CFTR modulator responses through pharmacomicrobiomics</b>	14:24 - 14:30
<i>Oral ePoster presenter:</i> Geneviève Héry-Arnaud (Brest, France)		
EPS8.06	<b>Crosstalk between carbapenem resistance and pathogenesis in <i>Pseudomonas aeruginosa</i></b>	14:30 - 14:36
<i>Oral ePoster presenter:</i> Pablo Laborda (Copenhagen, Denmark)		
EPS8.07	<b>Should asymptomatic first MRSA detection in cystic fibrosis</b>	14:36 - 14:42

**patients be treated? A 10-year single-center experience***Oral ePoster presenter:* Umay Kavgaci (Ankara, Turkey)

EPS8.08      **Susceptibility of *Pseudomonas aeruginosa* persistently colonizing patients with cystic fibrosis towards inhaled antibiotics and impact of antibiotic selective pressure**      14:42 - 14:48

*Oral ePoster presenter:* Vincent JEAN-PIERRE (Montpellier, France)

EPS8.09      **MRSA in CF affects lung function, with modulators showing limited impact, highlighting the need for further trials**      14:48 - 14:54

*Oral ePoster presenter:* Ceren Ayça Yıldız (Istanbul, Turkey)

EPS8.10      **In vitro exploration of *Lacticaseibacillus casei* AMBR2 as an airway probiotic for cystic fibrosis**      14:54 - 15:00

*Oral ePoster presenter:* Eline Cauwenberghs (Antwerp, Belgium)*Poster Viewing*

14:00 - 15:00

**Poster Viewing 2**

P259      **Evaluating changes in self-management preparedness, emotional burden, and confidence in achieving diabetes goals before and after a dietetic-led cystic fibrosis-related diabetes CFRD education clinic**      14:00 - 14:00

*Poster author:* Hannah Winterbottom (Manchester, United Kingdom)

P260      **Exploring patient preferences for structured diabetes education in cystic fibrosis: Insights from a local survey at Manchester Adult Cystic Fibrosis Centre (MACFC)**      14:00 - 14:00

*Poster author:* Hannah Winterbottom (Manchester, United Kingdom)

P261      **Colonoscopy screening outcomes in people with cystic fibrosis at the West Midlands Adult Cystic Fibrosis Centre**      14:00 - 14:00

*Poster author:* Angela Holden (Birmingham, United Kingdom)

P262      **Liver function among women with cystic fibrosis who use hormonal contraception**      14:00 - 14:00

*Poster author:* Ahmet Uluer (Seattle, United States)

P263      **Influence of elexacaftor/tezacaftor/ivacaftor on cystic fibrosis gastrointestinal (GI) Symptoms: a prospective cohort study**      14:00 - 14:00

*Poster author:* Kurdo Araz (Toronto, Canada)

P264      **Characterisation of the distal terminal ileum diameter in health and cystic fibrosis using magnetic resonance imaging**      14:00 - 14:00

*Poster author:* Madeleine Taylor (Nottingham, United Kingdom)

P265      **Dietary and nutritional quality in adults with cystic fibrosis undergoing colonoscopy**      14:00 - 14:00

*Poster author:* Nicole Taylor (Sydney, Australia)

P266      **Microbes, metabolites and inflammation in children with cystic fibrosis**      14:00 - 14:00

*Poster author:* Keith Chee Y. Ooi (Randwick, Australia)

P267      **Reactive hypoglycemia in cystic fibrosis**      14:00 - 14:00

*Poster author:* Andrea Foppiani (Milan, Italy)

P268      **The prevalence of hepatobiliary manifestations and their associated complications in cystic fibrosis**      14:00 - 14:00

*Poster author:* Evelien van der Hout (Utrecht, Netherlands)

P269      **Implementing bowel cancer screening at Bristol Adult Cystic Fibrosis Centre**      14:00 - 14:00

*Poster author:* Emma Connor (Bristol, United Kingdom)

P270	<b>UK adult CF centre experience of pharmacological weight management treatments in patients with cystic fibrosis diabetes</b>	14:00 - 14:00
<i>Poster author:</i> Harbinder Sunsoa (Birmingham, United Kingdom)		
P271	<b>A survey of diabetes technology used in cystic fibrosis centres across the UK</b>	14:00 - 14:00
<i>Poster author:</i> Harbinder Sunsoa (Birmingham, United Kingdom)		
P272	<b>Managing cardiovascular risk in adult cystic fibrosis centre care</b>	14:00 - 14:00
<i>Poster author:</i> Joanne Barrett (Birmingham, United Kingdom)		
P273	<b>Assessment of liver enzymes following initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Ivana Arnaudova Danevska (Skopje, North Macedonia)		
P274	<b>Muddying the waters with menopause! How important is addressing the menopause in terms of cystic fibrosis care: Antibiotics or hormone replacement therapy?</b>	14:00 - 14:00
<i>Poster author:</i> Becky Hemmings (Bristol, United Kingdom)		
P275	<b>New insights: lessons from pseudo-Bartter syndrome in infants with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Natalia S. Escobar (Toronto, Canada)		
P276	<b>Perceived gastrointestinal symptoms in people with cystic fibrosis before and after a 12-week course of a multistrain probiotic</b>	14:00 - 14:00
<i>Poster author:</i> Shahideh Safavi (London, United Kingdom)		
P277	<b>Exploring cystic fibrosis-specific cardiovascular risk in 'older' adults: Insights from a large UK CF Centre</b>	14:00 - 14:00
<i>Poster author:</i> Maeve O'Driscoll (London, United Kingdom)		
P278	<b>Trends in paediatric bone mineral density 2016-2024 - a single centre study</b>	14:00 - 14:00
<i>Poster author:</i> Anthony Brown (Belfast, United Kingdom)		
P279	<b>Efficacy and safety of CFTR modulators therapy in patients with Gilbert syndrome based on 2-year follow-up</b>	14:00 - 14:00
<i>Poster author:</i> Elena Zhekaite (Moscow, Russian Federation)		
P280	<b>Longitudinal follow-up of shear-wave elastography for predicting advanced CF liver disease in children</b>	14:00 - 14:00
<i>Poster author:</i> Silvia Gross (Brisbane, Australia)		
P281	<b>Bowel cancer screening protocol for the cystic fibrosis patient population: impact of the introduction of a protocol on number of required colonoscopies?</b>	14:00 - 14:00
<i>Poster author:</i> Lucy Johnston (Glasgow, United Kingdom)		
P282	<b>Clinical management of recently transitioned patients with CF diabetes: a single centre service evaluation</b>	14:00 - 14:00
<i>Poster author:</i> Joanna Snowball (Oxford, United Kingdom)		
P283	<b>Rethinking the annual review for the older CF population: A single centre service evaluation to inform clinical priorities</b>	14:00 - 14:00
<i>Poster author:</i> Joanna Snowball (Oxford, United Kingdom)		
P284	<b>An update on Dual Energy X-ray Absorptiometry (DEXA) screening rates and Bone Mineral Density (BMD) of the Northern Ireland (NI) cystic fibrosis (CF) population</b>	14:00 - 14:00
<i>Poster author:</i> Rebecca McSparron (Belfast, United Kingdom)		
P285	<b>Assessing potential of FIB-4 index and transient elastography for use in an adult cystic fibrosis population</b>	14:00 - 14:00
<i>Poster author:</i> Stephen Armstrong (Belfast, United Kingdom)		

P287	<b>Two-year longitudinal analysis of CFTR modulator therapy on liver fibrosis indices in children with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Vito Terlizzi (Firenze, Italy)		
P288	<b>Impact of elexacaftor/tezacaftor/ivacaftor on faecal pancreatic elastase in children with cystic fibrosis and pancreatic insufficiency aged 6-17 years: preliminary results from a single-centre study</b>	14:00 - 14:00
<i>Poster author:</i> Vito Terlizzi (Firenze, Italy)		
P289	<b>Effect of elexacaftor/tezacaftor/ivacaftor therapy on glycaemic status in CF: a single-centre retrospective study</b>	14:00 - 14:00
<i>Poster author:</i> Dorothea Appelt (Innsbruck, Austria)		
P290	<b>From insulin to oral medication in mild CFD - time to switch?</b>	14:00 - 14:00
<i>Poster author:</i> Paula Dyce (Liverpool, United Kingdom)		
P291	<b>A large single CF centre experience of DPP4 inhibitors in cystic fibrosis diabetes</b>	14:00 - 14:00
<i>Poster author:</i> Giulia Spoletini (Leeds, United Kingdom)		
P292	<b>Hybrid closed loop systems in adults with cystic fibrosis diabetes</b>	14:00 - 14:00
<i>Poster author:</i> Giulia Spoletini (Leeds, United Kingdom)		
P293	<b>Outcomes of a newly established cystic fibrosis related bone disease MDT: is it time to change?</b>	14:00 - 14:00
<i>Poster author:</i> Giulia Spoletini (Leeds, United Kingdom)		
P294	<b>French translation, validation and application of the CFAbd-Score® reveals a lower burden of gastrointestinal symptoms in patients treated with elexacaftor/tezacaftor/ivacaftor</b>	14:00 - 14:00
<i>Poster author:</i> Pauline Sadrieh (Brandenburg an der Havel, Germany)		
P295	<b>Early improvement in gastro-intestinal symptoms in 2-5 year old children following the introduction of elexacaftor/ tezacaftor/ ivacaftor (ETI)</b>	14:00 - 14:00
<i>Poster author:</i> Jenny O'Neill (London, United Kingdom)		
P296	<b>Improved glycaemic control following ETI therapy initiation in cystic fibrosis related diabetes patients</b>	14:00 - 14:00
<i>Poster author:</i> Vasiliki Kolovou (London, United Kingdom)		
P297	<b>Online breath analysis with PTR-TOF-MS for metabolic signatures in adults with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Stanislav Krasovsky (Moscow, Russian Federation)		
P298	<b>Comparative observational study of contemporaneous frequently sampled oral glucose tolerance test and continuous glucose monitoring in children and adults with CF - a study protocol</b>	14:00 - 14:00
<i>Poster author:</i> Klementina Ocskay (Budapest, Hungary)		
P299	<b>Hypoglycaemia during extended and frequently sampled oral glucose tolerance test in children with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Klementina Ocskay (Budapest, Hungary)		
P300	<b>The effect of cystic fibrosis transmembrane conductance regulator modulator therapy on glycaemic control in children with cystic fibrosis: a case-control study</b>	14:00 - 14:00
<i>Poster author:</i> Kiss Szabolcs (Budapest, Hungary)		
P301	<b>Real life application of the new cystic fibrosis hepatobiliary involvement score and its evolution over time</b>	14:00 - 14:00
<i>Poster author:</i> Stephanie Van Biervliet (Ghent, Belgium)		
P302	<b>Impact of elexacaftor/tezacaftor/ivacaftor treatment on liver function in pediatric cystic fibrosis patients: a real-life follow-up study</b>	14:00 - 14:00



Poster author: Stephanie Van Biervliet (Ghent, Belgium)

P303 **Does treatment with elexacaftor-tezacaftor-ivacaftor (ETI) started in adulthood affect liver health? A real-life follow-up study** 14:00 - 14:00

Poster author: Stephanie Van Biervliet (Ghent, Belgium)

P304 **Longitudinal impact of ursodeoxycholic acid on liver function in adults with cystic fibrosis: a retrospective analysis** 14:00 - 14:00

Poster author: Wai Tong Cheong (Frimley, United Kingdom)

P305 **Urinary sodium excretion in people with cystic fibrosis in the era of CFTR modulators** 14:00 - 14:00

Poster author: Valeria Dacco' (Milan, Italy)

P306 **The effect of polymorphisms of ACE, ACTN3, PPARA, PPARGC1A genes on the development of complications in patients with cystic fibrosis in the Russian Federation** 14:00 - 14:00

Poster author: Tatyana Y Maksimychева (Moscow, Russian Federation)

P307 **Rescue of F508del-CFTR function by elexacaftor-tezacaftor-ivacaftor in human intrahepatic cholangiocyte organoids** 14:00 - 14:00

Poster author: Erdene Baigal (Rotterdam, Netherlands)

P308 **Effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycaemic control in children with cystic fibrosis: a promising trend towards improved glucose regulation** 14:00 - 14:00

Poster author: Jasna Rodman Berlot (Ljubljana, Slovenia)

P309 **Changes in faecal elastase following initiation of CFTR modulator therapy in paediatric patients with cystic fibrosis** 14:00 - 14:00

Poster author: Katie Harriman (Bristol, United Kingdom)

P310 **Variability in Faecal Elastase (FE-1) in a paediatric cystic fibrosis (CF) population commencing CFTR modulators** 14:00 - 14:00

Poster author: Lucy Paskin (Birmingham, United Kingdom)

P311 **A case series of Gilbert's syndrome identified after commencing elexacaftor/tezacaftor/ivacaftor in a regional paediatric centre** 14:00 - 14:00

Poster author: Laura Jenkins (Belfast, United Kingdom)

P312 **Impact of age at initiation of elexacaftor/tezacaftor/ivacaftor on pancreatic enzyme function in children with cystic fibrosis** 14:00 - 14:00

Poster author: Charlotte Walker (London, United Kingdom)

P313 **Role of elexacaftor/tezacaftor/ivacaftor therapy on faecal Elastase-1 and fat-soluble vitamins in children with cystic fibrosis** 14:00 - 14:00

Poster author: Sanem Eryilmaz Polat (Ankara, Turkey)

P314 **Assessment of nutritional impact and total cholesterol levels in patients with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor: a retrospective observational study** 14:00 - 14:00

Poster author: Nicola Perrotta (Rome, Italy)

P315 **Food insecurity in the pediatric cystic fibrosis population in British Columbia, Canada** 14:00 - 14:00

Poster author: Zoë Maika (Vancouver, Canada)

P316 **The link between food insecurity and nutrition in children with cystic fibrosis** 14:00 - 14:00

Poster author: Damla Kocaman (Istanbul, Turkey)

P317 **Evolving nutritional needs in the era of CFTR modulators** 14:00 - 14:00

Poster author: Benedetta Fabrizzi (Ancona, Italy)

P318 **Assessment of nutritional status (NS) and body composition of children with cystic fibrosis (CF) on the background of targeting** 14:00 - 14:00

**therapy (TT)**

*Poster author:* Nataliya Kashirskaya (Moscow, Russian Federation)

P319                    **The impact of neonatal screening on nutritional status in cystic fibrosis patients in North Macedonia**                    14:00 - 14:00

*Poster author:* Lidija Spirevska (Skopje, North Macedonia)

P320                    **What do CF patients eat for breakfast in the era of highly effective modulator therapy? - experience from the Center for cystic fibrosis children and adults, UHC, Zagreb**                    14:00 - 14:00

*Poster author:* Andrea Vukic Dugac (Zagreb, Croatia)

P322                    **Beyond vitamin D - nutritional factors influencing bone health in people with cystic fibrosis**                    14:00 - 14:00

*Poster author:* Moshe Heching (Petach Tikva, Israel)

P323                    **European practices in vitamin supplementation for cystic fibrosis since the introduction of CFTR modulators**                    14:00 - 14:00

*Poster author:* Chris Smith (Brighton, United Kingdom)

P324                    **Vitamin A deficiency and *Mycobacterium abscessus***                    14:00 - 14:00

*Poster author:* Jennifer Still (Aberdeen, United Kingdom)

P325                    **Nutritional status with specific focus in fat soluble vitamins in Swedish patients with cystic fibrosis - a registry study**                    14:00 - 14:00

*Poster author:* Mikael Nilsson (Lund, Sweden)

P326                    **Audit of children with cystic fibrosis taking fat soluble vitamin preparation at Alder Hey Children's Hospital to determine if modulator therapy, age or genotype are predictors of high vitamin levels**                    14:00 - 14:00

*Poster author:* Clare J Woodland (Liverpool, United Kingdom)

P327                    **Impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamins and weight in individuals with cystic fibrosis: a pilot study**                    14:00 - 14:00

*Poster author:* Kristina Nilsson (Stockholm, Sweden)

P328                    **Implementing and evaluating a protocol to convert adult people with cystic fibrosis to bespoke 'all in one' combined fat-soluble vitamin products**                    14:00 - 14:00

*Poster author:* Chloe Knorz (Cardiff, United Kingdom)

P329                    **Do we prescribe too many vitamin A & E supplements?**                    14:00 - 14:00

*Poster author:* Abigail Owen (Plymouth, United Kingdom)

P330                    **Hypervitaminosis A in children with cystic fibrosis caused by a combination of all-in-one fat-soluble vitamin supplements and elexacaftor/tezacaftor/ivacaftor**                    14:00 - 14:00

*Poster author:* Hannah Joscelyne (Stoke on Trent, United Kingdom)

P331                    **This study investigates the long-term impact of targeted nutritional interventions on BMI percentiles in children with cystic fibrosis**                    14:00 - 14:00

*Poster author:* Seyda Karabulut (Istanbul, Turkey)

P332                    **Quality of diet in children with Cystic Fibrosis (CF) in a socially deprived area in the North East of England**                    14:00 - 14:00

*Poster author:* Jessica Prout (Middlesbrough, United Kingdom)

P333                    **Scoping review protocol: Diet composition and quality in children with cystic fibrosis in the modulator era**                    14:00 - 14:00

*Poster author:* Laura Schembri (London, United Kingdom)

P334                    **Dynamics of bone mineral density indicators after one year of CFTR modulator therapy**                    14:00 - 14:00

*Poster author:* Elena Zhekaite (Moscow, Russian Federation)

P335	<b>Changes in body composition in people with cystic fibrosis since commencing elexacaftor/tezacaftor/ivacaftor: a systematic review</b>	14:00 - 14:00
<i>Poster author:</i> Hannah King (Nottingham, United Kingdom)		
P336	<b>An international dietetic survey on current practices for managing bone health in individuals with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Hannah Winterbottom (Manchester, United Kingdom)		
P337	<b>Dynamics of body composition in children with cystic fibrosis after receiving targeted therapy for 1 year</b>	14:00 - 14:00
<i>Poster author:</i> Tatyana Y Maksimychева (Moscow, Russian Federation)		
P338	<b>The effect of elexacaftor/tezacaftor/ivacaftor therapy on the anthropometric measures in individuals with cystic fibrosis: a systematic review</b>	14:00 - 14:00
<i>Poster author:</i> Kate Kinsella (Chester, United Kingdom)		
P339	<b>Assessing the change in body composition and lung function in adults with cystic fibrosis (CF) pre and post initiation of elexacaftor/tezacaftor/ivacaftor (ETI)</b>	14:00 - 14:00
<i>Poster author:</i> Lauren Alberts (London, United Kingdom)		
P340	<b>Exploring changes in body composition in adults with cystic fibrosis using elexacaftor/tezacaftor/ivacaftor</b>	14:00 - 14:00
<i>Poster author:</i> Marleen Broekhuizen (Utrecht, Netherlands)		
P341	<b>Body composition and handgrip strength among children and adolescents with cystic fibrosis: correlation with anthropometric parameters and disease severity</b>	14:00 - 14:00
<i>Poster author:</i> Elpis Hatziagorou (Thessaloniki, Greece)		
P342	<b>A systematic review of the impact of elexacaftor/tezacaftor/ivacaftor on body composition in individuals with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Hannah Winterbottom (Manchester, United Kingdom)		
P343	<b>Poor agreement between dual-energy x-ray absorptiometry and bioelectrical impedance analysis for assessing body fat mass in children and adolescents with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Uros Krivec (Ljubljana, Slovenia)		
P344	<b>Pancreatic function and fat-soluble vitamin levels in 2-6-year-old-children with cystic fibrosis starting elexacaftor/tezacaftor/ivacaftor</b>	14:00 - 14:00
<i>Poster author:</i> Laura Schembri (London, United Kingdom)		
P345	<b>Increasing prevalence of pancreatic sufficiency in a paediatric CF unit - are CFTR modulators the cause?</b>	14:00 - 14:00
<i>Poster author:</i> Niamh Lydon (Glasgow, United Kingdom)		
P346	<b>The link between fat intake and pancreatic enzyme replacement dosage with growth in children with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Damla Kocaman (Istanbul, Turkey)		
P347	<b>Management of Pancreatic Enzyme Replacement Therapy (PERT) Shortages in a large UK Adult Cystic Fibrosis (CF) Centre: an imPERaTive approach</b>	14:00 - 14:00
<i>Poster author:</i> Dee Shimmin (Leeds, United Kingdom)		
P348	<b>Current dietetic practices in managing pancreatic enzyme replacement therapy across the United Kingdom</b>	14:00 - 14:00
<i>Poster author:</i> Paige Elliott (Newcastle, United Kingdom)		
P349	<b>Insight on weight gain in children and adolescents with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor: a prospective cohort study</b>	14:00 - 14:00
<i>Poster author:</i> Sylvain Blanchon (Lausanne, Switzerland)		

P350	<b>Growth and infant feeding method in infants with unmodulated cystic fibrosis (CF) referred to a regional CF network centre</b>	14:00 - 14:00
<i>Poster author:</i> Fiona Bartlett (London, United Kingdom)		
P351	<b>The use of tube feeding after starting elexacaftor/tezacaftor/ivacaftor in a Belgian paediatric and adult cohort living with CF</b>	14:00 - 14:00
<i>Poster author:</i> Dimitri Declercq (Gent, Belgium)		
P352	<b>Effect of ACE, ACTN3, PPARA, PPARGC1A gene polymorphisms on nutritional status in patients with cystic fibrosis in the Russian Federation</b>	14:00 - 14:00
<i>Poster author:</i> Tatyana Y Maksimychева (Moscow, Russian Federation)		
P353	<b>From gut feeling to hard evidence: a journey through poop in CF</b>	14:00 - 14:00
<i>Poster author:</i> Caroline Powell (Cardiff, United Kingdom)		
P354	<b>Never assume, check; Implementing and evaluating a healthy lifestyle survey in an adult population with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Chloe Knorz (Cardiff, United Kingdom)		
P355	<b>Cardiometabolic complications in an adult, Northern Ireland population with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Veronica Lynch (Belfast, United Kingdom)		
P356	<b>Patient satisfaction and experience of a liquid soluble fibre supplement for reported gastro-intestinal (GI) symptoms in a regional adult CF service: results from an online survey</b>	14:00 - 14:00
<i>Poster author:</i> Alice Moull (Leeds, United Kingdom)		
P357	<b>Feeding practices, behaviours and disorders in infants and children with cystic fibrosis. A scoping review</b>	14:00 - 14:00
<i>Poster author:</i> Caitlin Miles (Clayton, Australia)		
P358	<b>Changing practice in salt supplementation in a UK cystic fibrosis paediatric centre</b>	14:00 - 14:00
<i>Poster author:</i> Claire Berry (Liverpool, United Kingdom)		
P359	<b>Strength post modulator therapy</b>	14:00 - 14:00
<i>Poster author:</i> Ezequiel Baran (La Plata, Argentina)		
P360	<b>Anthropometric and lung function outcomes in children started on elexacaftor/tezacaftor/ivacaftor at a single UK cystic fibrosis centre</b>	14:00 - 14:00
<i>Poster author:</i> Christopher Jolley (Stoke on Trent, United Kingdom)		
P361	<b>Similarities and differences in the practice of senior and specialist dietitians working in cystic fibrosis (CF) in this post-CFTR era - a cross-sectional survey</b>	14:00 - 14:00
<i>Poster author:</i> Audrey Tierney (Limerick, Ireland)		
P362	<b>SOLAR: A non-interventional study of long-term outcomes in people with cystic fibrosis aged 6 years and older treated with ELX/TEZ/IVA using data from the National French CF Registry</b>	14:00 - 14:00
<i>Poster author:</i> Conor Daly (Boston, United States)		
P363	<b>Changes in prescription of inhaled antibiotics between 2012-2019 in the European Cystic Fibrosis Patient Registry</b>	14:00 - 14:00
<i>Poster author:</i> Marianne S. Muhlebach (Chapel Hill, United States)		
P364	<b>Emergent airway infections with chronic inhaled antibiotics</b>	14:00 - 14:00
<i>Poster author:</i> Marianne S. Muhlebach (Chapel Hill, United States)		
P365	<b>Expanding access to high-quality cystic fibrosis care in Argentina: outcomes of a train-the-trainer program</b>	14:00 - 14:00
<i>Poster author:</i> Hector Gutierrez (Birmingham, United States)		

P366	<b>Development and delivery of a cystic fibrosis team mentorship curriculum: evaluating training modalities</b>	14:00 - 14:00
<i>Poster author:</i> Hector Gutierrez (Birmingham, United States)		
P367	<b>The impact of adopting the GLI-Global race-neutral equation to calculate percent predicted Forced Expiratory Volume in 1 second (ppFEV<sub>1</sub>) at the West Midlands Adult Cystic Fibrosis Centre (WMAFC)</b>	14:00 - 14:00
<i>Poster author:</i> Catherine Brown (Birmingham, United Kingdom)		
P368	<b>Data quality in clinical spirometry: a retrospective audit at the West Midlands Adult Cystic Fibrosis Centre (WMAFC)</b>	14:00 - 14:00
<i>Poster author:</i> Catherine Brown (Birmingham, United Kingdom)		
P369	<b>How not to overlook a person with cystic fibrosis eligible for CFTR modulator therapy in a cystic fibrosis registry</b>	14:00 - 14:00
<i>Poster author:</i> Alena Bilkova (Prague, Czech Republic)		
P370	<b>Minimal variability in the use of digital health devices between generations among people with cystic fibrosis (pwCF): a single centre audit</b>	14:00 - 14:00
<i>Poster author:</i> Jenna Galloway (London, United Kingdom)		
P371	<b>Introducing the ENHANCE study - establishing the natural history of childhood CF in a new era of care</b>	14:00 - 14:00
<i>Poster author:</i> Paul McNally (Dublin, Ireland)		
P373	<b>Does visualising lung function and Body mass index (BMI) trends using the 'My report' section on the cystic fibrosis registry database help clinical decision making and improve the patient experience</b>	14:00 - 14:00
<i>Poster author:</i> Penny Galey (Norwich, United Kingdom)		
P376	<b>Exercise testing for cystic fibrosis in the UK: a registry-based analysis</b>	14:00 - 14:00
<i>Poster author:</i> Owen Tomlinson (Exeter, United Kingdom)		
P377	<b>Target trial emulation: optimising methods for estimating treatment effects using data from the UK CF Registry</b>	14:00 - 14:00
<i>Poster author:</i> Emily Granger (London, United Kingdom)		
P378	<b>Totally implantable venous access devices in adults with cystic fibrosis: a 10-year study evaluating changes in use over time and their ongoing role in the era of modulator therapy</b>	14:00 - 14:00
<i>Poster author:</i> Shweta Agrawal (London, United Kingdom)		
P379	<b>TIDES 2.0: prevalence and longitudinal course of depression, anxiety, and behaviour problems in children with cystic fibrosis (CF) under 12 years of age</b>	14:00 - 14:00
<i>Poster author:</i> Alexandra L. Quittner (Hollywood, United States)		
P380	<b>Real-life effectiveness and safety of lumacaftor/ivacaftor in paediatric F/F cystic fibrosis: preliminary data from an Italian multicentre study</b>	14:00 - 14:00
<i>Poster author:</i> Vito Terlizzi (Firenze, Italy)		
P381	<b>Changes in pulmonary outcomes of patients treated at the Warsaw Paediatric CF Centre in the era of CFTR modulators based on the European Cystic Fibrosis Society Patient Registry</b>	14:00 - 14:00
<i>Poster author:</i> Katarzyna Walicka-Serzysko (Warsaw, Poland)		
P382	<b>The main characteristics of cystic fibrosis patients from the Republic of Moldova</b>	14:00 - 14:00
<i>Poster author:</i> Cristina Tomacinschii (Chisinau, Moldova)		
P383	<b>Incidence of cystic fibrosis in Brittany (western France): overview</b>	14:00 - 14:00

	<b>of 50 years of monitoring and 35 years of newborn screening</b>	
	<i>Poster author:</i> Virginie Scotet (Brest, France)	
P384	<b>Evaluation of rare cystic fibrosis transmembrane conductance regulator gene variants according to seven functional classes from Turkish National Cystic Fibrosis Patient Registry</b>	14:00 - 14:00
	<i>Poster author:</i> Burcu Capraz Yavuz (Ankara, Turkey)	
P385	<b>Clinical characteristics of cystic fibrosis children with intermediate sweat chloride test</b>	14:00 - 14:00
	<i>Poster author:</i> Tugce Kantemir (Ankara, Turkey)	
P386	<b>Health outcomes for PwCF switching from a CFTR modulator therapy (CFTRm) to elexaftor/tezacaftor/ivacaftor (ETI) compared with those starting on ETI naively. A study using Irish registry data</b>	14:00 - 14:00
	<i>Poster author:</i> Paul O'Regan (Dublin, Ireland)	
P387	<b>Ensuring Excellence: The Data Quality Programme of the cystic fibrosis Registry of Ireland</b>	14:00 - 14:00
	<i>Poster author:</i> Laura Kirwan (Dublin, Ireland)	
P388	<b>Physiotherapy data collection: could registry data improve future physiotherapy outcomes? Views from the Irish CF registry</b>	14:00 - 14:00
	<i>Poster author:</i> Laura Kirwan (Dublin, Ireland)	
P389	<b>Safeguarding the future of patient registries: lessons from the cystic fibrosis registry of Ireland and the work of the future of registries taskforce</b>	14:00 - 14:00
	<i>Poster author:</i> Robyn Doherty (Dublin, Ireland)	
P390	<b>The path to prevention: people with cystic fibrosis with a primary care physician are more likely to be screened for cancer in Canada</b>	14:00 - 14:00
	<i>Poster author:</i> Stephanie Y. Cheng (Toronto, Canada)	
P391	<b>The remaining 4%: despite an expanded indication and access elexacaftor/tezacaftor/ivacaftor in Canada, 200 patients must not be left behind</b>	14:00 - 14:00
	<i>Poster author:</i> Stephanie Y. Cheng (Toronto, Canada)	
P392	<b>Updating care guidelines for cystic fibrosis in Canada: an interdisciplinary approach</b>	14:00 - 14:00
	<i>Poster author:</i> Paul Eckford (Toronto, Canada)	
P393	<b>First step of the Montpellier (France) and Vinnytsia (Ukraine) Europe's European Twinning Expansion project</b>	14:00 - 14:00
	<i>Poster author:</i> Raphael Chiron (Montpellier, France)	
P394	<b>Quality of life—there remains a gap between females and males living with Cystic Fibrosis</b>	14:00 - 14:00
	<i>Poster author:</i> Nikolas Johl (Cardiff, United Kingdom)	
P395	<b>Clinical characteristics of children with cystic fibrosis in Kazakhstan</b>	14:00 - 14:00
	<i>Poster author:</i> Elena Amelina (Astana, Kazakhstan)	
P396	<b>Characteristics of adults with cystic fibrosis in Kazakhstan</b>	14:00 - 14:00
	<i>Poster author:</i> Irina Mukatova (Astana, Kazakhstan)	
P397	<b>Accessibility and distribution of donated highly effective modular therapy in Lebanon</b>	14:00 - 14:00
	<i>Poster author:</i> Salman Mroueh (Beirut, Lebanon)	
P398	<b>Chronic Kidney Disease and eGFR trajectories in people with cystic fibrosis. A single centre retrospective analysis</b>	14:00 - 14:00
	<i>Poster author:</i> Nikolas Johl (Cardiff, United Kingdom)	

P399	<b>Longitudinal association between mental health, respiratory outcomes, sleep, and quality of life in adolescents with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Hiep Pham (Melbourne, Australia)		
P400	<b>Anxiety levels in mothers of children with positive cystic fibrosis newborn screening</b>	14:00 - 14:00
<i>Poster author:</i> Ayse Tana Aslan (Ankara, Turkey)		
P401	<b>Your life and CF 2024: analysis of 2024 adult and youth survey data</b>	14:00 - 14:00
<i>Poster author:</i> Eleanor Lee Mindel (London, United Kingdom)		
P402	<b>Cost burden and cystic fibrosis: a comparison between the United States and the United Kingdom</b>	14:00 - 14:00
<i>Poster author:</i> Olivia Dieni (Bethesda, United States)		
P403	<b>Quality of life and anxious-depressive symptoms in cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Cristiana Risso (Torino, Italy)		
P404	<b>Dietary patterns and family interactions in children and adolescents with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Cristiana Risso (Torino, Italy)		
P405	<b>Depressive symptoms in adolescents and adults before and during the COVID-19 pandemic in a US cystic fibrosis center</b>	14:00 - 14:00
<i>Poster author:</i> Jianghua He (Kansas City, United States)		
P406	<b>Rates of depression and anxiety among people with cystic fibrosis in Ireland, assessed with the PHQ-9 and GAD-7</b>	14:00 - 14:00
<i>Poster author:</i> Daniel Goldstone (Dublin, Ireland)		
P407	<b>Mental health in 2-5 year-old children with cystic fibrosis initiating elexacaftor/ tezacaftor/ ivacaftor at British Columbia Children's Hospital, Canada</b>	14:00 - 14:00
<i>Poster author:</i> Anna Gravelle (Vancouver, Canada)		
P408	<b>The relation of caregiver mental health to adolescent mental and behavioural health outcomes in the era of elexacaftor/tezacaftor/ ivacaftor (ETI)</b>	14:00 - 14:00
<i>Poster author:</i> Christina Duncan (Stillwater, United States)		
P409	<b>Mental health in those taking CFTR modulators following the COVID-19 pandemic. A cross-sectional study across a whole centre cohort of adults with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Robert David Sandler (Sheffield, United Kingdom)		
P410	<b>Mental/behavioral health and adherence to elexacaftor/tezacaftor/ivacaftor (ETI) among Your ETI (yETI) study participants</b>	14:00 - 14:00
<i>Poster author:</i> Robin Everhart (Richmond, United States)		
P411	<b>Childhood experiences and reproductive decision-making in the era of CFTR modulators therapy in Germany</b>	14:00 - 14:00
<i>Poster author:</i> Josephine Stark (Neuruppin, Germany)		
P412	<b>Body image in the era of modulator therapies - a systematic review in young people and adults with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Cian Greaney (Limerick, Ireland)		
P413	<b>A qualitative exploration of the experiences of adults with cystic fibrosis unable to benefit from triple combination therapy</b>	14:00 - 14:00
<i>Poster author:</i> Mulongwe Mwelwa (Cardiff, United Kingdom)		
P414	<b>What is the impact of new cystic fibrosis transmembrane conductance regulator modulator therapies on the psychological well-being of children with cystic fibrosis and their parents?</b>	14:00 - 14:00

Poster author: Tim Lee (Leeds, United Kingdom)

P415 **Review of reported behavioural issues and management strategies in patients on elexacaftor/tezacaftor/ivacaftor (ETI) from a UK paediatric cystic fibrosis (CF) clinic** 14:00 - 14:00

Poster author: Lucy Paskin (Birmingham, United Kingdom)

P417 **Evaluation of modulator therapy on mental health of patients with cystic fibrosis and their caregivers** 14:00 - 14:00

Poster author: Hande Yetişgin (Ankara, Turkey)

P418 **Recalibrating “a whole new life”: exploring the impact of elexacaftor/tezacaftor/ivacaftor on self-concept for adults with cystic fibrosis** 14:00 - 14:00

Poster author: Melanie Jessup (Hamilton, New Zealand)

P420 **Am I ill or do I feel ill: long-term change in illness perception and illness identity after initiation of elexacaftor/tezacaftor/ivacaftor and the impact on mental wellbeing and quality of life** 14:00 - 14:00

Poster author: Els van der Heijden (Utrecht, Netherlands)

P421 **Accessing impact of elexacaftor/tezacaftor/ivacaftor therapy on antidepressant usage in an adult cystic fibrosis population** 14:00 - 14:00

Poster author: Stephen Armstrong (Belfast, United Kingdom)

P422 **Clinician perspectives on care of adults with cystic fibrosis in the post-elexacaftor/tezacaftor/ivacaftor era** 14:00 - 14:00

Poster author: Robert David Sandler (Sheffield, United Kingdom)

P423 **We are cystic fibrosis (CF) Patients: the mood of our life** 14:00 - 14:00

Poster author: Paola Catastini (Leghorn, Italy)

P424 **Effects of elexacaftor/tezacaftor/ivacaftor (ETI) on CFQ-R results in pediatric cystic fibrosis patients: a single center retrospective analysis** 14:00 - 14:00

Poster author: Annemarie M. Tiesinga-van der Lijn (Groningen, Netherlands)

P425 **Mental health issues in children aged 6 to 12 on triple modulator therapy in Bulgaria** 14:00 - 14:00

Poster author: Guergana Petrova (Sofia, Bulgaria)

P426 **Factors associated with adherence to inhaled therapy in the post-CFTR modulator era: a cross-sectional study including a whole centre of adults with cystic fibrosis** 14:00 - 14:00

Poster author: Robert David Sandler (Sheffield, United Kingdom)

P427 **Associations between medication beliefs and adherence to elexacaftor/tezacaftor/ ivacaftor (ETI)** 14:00 - 14:00

Poster author: Kristin Riekert (Baltimore, United States)

P428 **My medicines.... what matters to me: a modified Experience-Based Co-Design approach to support long-term adherence to oral medication with a focus on CFTR modulators in adults with cystic fibrosis** 14:00 - 14:00

Poster author: Daniel Peckham (Leeds, United Kingdom)

P429 **Sustained three-year real-world adherence to elexacaftor/tezacaftor/ivacaftor in adolescents with cystic fibrosis** 14:00 - 14:00

Poster author: Amanda Bevan (Southampton, United Kingdom)

P430 **Adherence to inhaled therapies in children and young people with cystic fibrosis in the era of CFTR modulators: an online survey** 14:00 - 14:00

Poster author: Sarah Lužar (Ljubljana, Slovenia)

P431 **Self-reported CFTR modulator use in a UK adult CF population** 14:00 - 14:00

Poster author: Louise Warnock (Oxford, United Kingdom)



P432	<b>Facilitators and barriers for medication adherence in people with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Carina M.E. Hansen (Groningen, Netherlands)		
P433	<b>Adherence challenges of paediatric patients - Cystic Fibrosis Centre Zagreb experience</b>	14:00 - 14:00
<i>Poster author:</i> Dolores Bzik (Zagreb, Croatia)		
P434	<b>Exploring the treatment experiences of adolescents living with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Jade Alexander (Belfast, United Kingdom)		
P435	<b>ACT with CF: a comprehensive clinician training program for an evidence-based targeted mental health intervention for adults with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> C. Virginia O'Hayer (Philadelphia, United States)		
P436	<b>Characteristics associated with reporting a minimally important difference in depression or anxiety following a CF-specific stress management program</b>	14:00 - 14:00
<i>Poster author:</i> CJ Bathgate (Denver, United States)		
P437	<b>The effect of group psychotherapy on anxiety, depression, and quality of life in cystic fibrosis: a pilot study</b>	14:00 - 14:00
<i>Poster author:</i> Eda Esra Baysal (Istanbul, Turkey)		
P438	<b>Online Paws b mindfulness group for children with cystic fibrosis and siblings aged 7-11 years</b>	14:00 - 14:00
<i>Poster author:</i> Sally Harris (Brighton, United Kingdom)		
P439	<b>The role of the Research Play Specialist in CF Clinic, helping children and adolescents to develop coping strategies to overcome some of their anxieties in relation to blood sampling and beyond</b>	14:00 - 14:00
<i>Poster author:</i> Lynda Elliott (Nottingham, United Kingdom)		
P440	<b>Capsules, confidence and cystic fibrosis: reflections on setting up a pill school</b>	14:00 - 14:00
<i>Poster author:</i> Caroline Powell (Cardiff, United Kingdom)		
P441	<b>Assistive technology for everyday life activities in cystic fibrosis - what do we know?</b>	14:00 - 14:00
<i>Poster author:</i> Wendy Foo (Manchester, United Kingdom)		
P442	<b>Peer support through digital connection - facilitating spaces for parents with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Rachel Massey-Chase (London, United Kingdom)		
P443	<b>CF Summer School</b>	14:00 - 14:00
<i>Poster author:</i> Michal Tevet (Haifa, Israel)		
P444	<b>Preliminary validation of the general mental health screener (GEMS-CF): frequency and impact of mental health comorbidities in a diverse sample of adults with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Alexandra L. Quittner (Hollywood, United States)		
P445	<b>AWESCORE - all-Wales adult cystic fibrosis service experience of using AWESCORE to assess quality of life in people living with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Nikolas Johl (Cardiff, United Kingdom)		
P446	<b>Quality of life changes after inpatient treatment for infective exacerbation of cystic fibrosis using AWESCORE</b>	14:00 - 14:00
<i>Poster author:</i> Nikolas Johl (Cardiff, United Kingdom)		
P447	<b>A screening tool: the biopsychosocial impacts of CFTR modulators on people with CF</b>	14:00 - 14:00

Poster author: Stephen Moss (Belfast, United Kingdom)

P448                    **Partnering, pregnancy and parenthood for women with cystic fibrosis**                    14:00 - 14:00

Poster author: Stephen Bourke (Newcastle upon Tyne, United Kingdom)

P449                    **What do people with CF value and wish to develop in a dedicated Reproductive & Maternal Health Service (RMHS)?**                    14:00 - 14:00

Poster author: Amy Downes (London, United Kingdom)

P450                    **Evaluation of care in pregnancy for patients with cystic fibrosis - can we do better?**                    14:00 - 14:00

Poster author: Rachel Pettit (Liverpool, United Kingdom)

P451                    **Discussion of women's health issues with adolescents with cystic fibrosis**                    14:00 - 14:00

Poster author: Anna Shawcross (Manchester, United Kingdom)

P452                    **Female sexual reproductive health in cystic fibrosis: from menstruation to menopause with technology**                    14:00 - 14:00

Poster author: Cicely Mathews (Southampton, United Kingdom)

P453                    **A study on patient and healthcare provider experiences with outpatient sexual and reproductive healthcare for adults with cystic fibrosis: insights from a single-center study**                    14:00 - 14:00

Poster author: Cune Verbeek (Utrecht, Netherlands)

P454                    **The impact of parenting on short-term health outcomes in people with cystic fibrosis**                    14:00 - 14:00

Poster author: Ivana Lalic Cickovic (Zagreb, Croatia)

P455                    **Evaluation of pregnancy and outcome in Dutch people with cystic fibrosis using elexacaftor/tezacaftor/ivacaftor during conception period and pregnancy**                    14:00 - 14:00

Poster author: Suzan Schotman (Utrecht, Netherlands)

P456                    **Enhanced participation and understanding of cystic fibrosis among families through access to health data**                    14:00 - 14:00

Poster author: Frida Lundqvist (Gothenburg, Sweden)

P457                    **Health literacy of adult cystic fibrosis patients: insights from UHC Zagreb**                    14:00 - 14:00

Poster author: Tihana Odobasic Palkovic (Zagreb, Croatia)

P458                    **A scientists and patients/relatives meeting for more targeted research**                    14:00 - 14:00

Poster author: Estelle Ruffier (Paris, France)

P459                    **Therapeutic education for cystic fibrosis: deployment of parent/patient - caregiver peers in France**                    14:00 - 14:00

Poster author: Marie GABORIT (Paris, France)

P460                    **Exploring the barriers and enablers of optimal healthcare transition from the perspectives of young people and parents in this new era of treatment**                    14:00 - 14:00

Poster author: Caroline Heary (Galway, Ireland)

P461                    **All About Me: a new tool designed to amplify the patient's voice as they transition from paediatric cystic fibrosis (CF) services across Wessex to the adult service at University Hospital Southampton**                    14:00 - 14:00

Poster author: Sop Sinnott (Southampton, United Kingdom)

P462                    **Contributions of a pharmacist to annual reviews in a UK paediatric cystic fibrosis team**                    14:00 - 14:00

Poster author: Chloe Benn (London, United Kingdom)

P463	<b>Parental views on the initiation of nurse-led parallel clinics</b>	14:00 - 14:00
<i>Poster author:</i> Ann-Marie Martin (Birmingham, United Kingdom)		
P464	<b>Experiences of adult cystic fibrosis care in the United Kingdom</b>	14:00 - 14:00
<i>Poster author:</i> Sarah Clarke (London, United Kingdom)		
P465	<b>Oral health and access to dental services; the perspective of adults with cystic fibrosis (awCF) at a regional adult CF Centre</b>	14:00 - 14:00
<i>Poster author:</i> Ian Clifton (Leeds, United Kingdom)		
P466	<b>The role of telemonitoring in preventing lung function reduction in cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Elpis Hatziagorou (Thessaloniki, Greece)		
P467	<b>Updating the consensus document: standards for the nursing management of cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Caroline Whitton (Plymouth, United Kingdom)		
P468	<b>Beyond the wait: evaluating the clinic experience for families and children with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Alex Macdonald (Worcester, United Kingdom)		
P469	<b>An evaluation of the supervision arrangements for social work members of the United Kingdom psychosocial professionals in cystic fibrosis group</b>	14:00 - 14:00
<i>Poster author:</i> Claire Oliver (Southampton, United Kingdom)		
P470	<b>Addressing gaps in clinical psychology provision - providing information for commissioners, clinical directors and the cystic fibrosis community</b>	14:00 - 14:00
<i>Poster author:</i> Rachel Massey-Chase (London, United Kingdom)		
P472	<b>Changes in a paediatric outreach service pre &amp; post CFTR modulators</b>	14:00 - 14:00
<i>Poster author:</i> Lynsay Houlihan (London, United Kingdom)		
P473	<b>Health care professionals' perceptions of the process of conferring a diagnosis of cystic fibrosis to families: current practice and changes over time</b>	14:00 - 14:00
<i>Poster author:</i> Steve Jones (Sheffield, United Kingdom)		
P475	<b>A review of use and maintenance of totally implantable venous access devices in people with cystic fibrosis</b>	14:00 - 14:00
<i>Poster author:</i> Rita Mele (Leeds, United Kingdom)		
P476	<b>Results from the psychological intervention study</b>	14:00 - 14:00
<i>Poster author:</i> Carsten Schwarz (Potsdam, Germany)		

*Workshop*  
15:00 - 16:30

**WS10 - WS10 - Targeting inflammation and immunity in cystic fibrosis**

*Moderator:* Wendy Unger (Rotterdam, Netherlands)

*Moderator:* Marcus A. Mall (Berlin, Germany)

WS10.01	<b>Microbial tolerance in cystic fibrosis airways is imprinted by a new type of immune memory and can be countered by novel host-directed therapy</b>	15:00 - 15:15
<i>Oral abstract presenter:</i> Rabin Tirouvanziam (Atlanta, United States)		
WS10.02	<b>Proteomic analysis of nasal lavage fluid and sputum samples in people with cystic fibrosis during 24 months of treatment with elxecaftor/tezacaftor/ivacaftor - The RECOVER study</b>	15:15 - 15:30
<i>Oral abstract presenter:</i> Samuel Nolan (Belfast, United Kingdom)		
WS10.03	<b>Shifts in systemic inflammatory profiles on</b>	15:30 - 15:45

**elexacaftor/tezacaftor/ivacaftor predict clinical outcomes in cystic fibrosis***Oral abstract presenter:* Leander Jonckheere (Ghent, Belgium)

WS10.04      **Programmed cell death 1 receptor axis blockade enhances antigen-specific T cell proliferation in paediatric cystic fibrosis**      15:45 - 16:00

*Oral abstract presenter:* Edona Cahani (Lausanne, Switzerland)

WS10.05      **Downregulation of inflammatory cytokines and miRNAs by novel inhalable formulations bearing Iloprost in primary human cystic fibrosis nasal epithelial cells**      16:00 - 16:15

*Oral abstract presenter:* Annalucia Carbone (Foggia, Italy)

WS10.06      **Pre-clinical validation of GY971, a new anti-inflammatory agent targeting Nuclear Factor kappa B (NF-κB)**      16:15 - 16:30

*Oral abstract presenter:* Chiara Tupini (Ferrara, Italy)*Workshop*

15:00 - 16:30

**WS11 - WS11 - Infectious dynamics of cystic fibrosis pathogens***Moderator:* Geneviève Héry-Arnaud (Brest, France)*Moderator:* Elio Rossi (Milan, Italy)

WS11.01      **Matrix meltdown: Biofilm degradation to aid antibiotic efficacy in *Pseudomonas aeruginosa* lung infection**      15:00 - 15:15

*Oral abstract presenter:* Isaac Martin (Toronto, Canada)

WS11.02      **Lack of *sirB2* gene stimulates virulence, invasion, and small colony variants emergence in *Pseudomonas aeruginosa***      15:15 - 15:30

*Oral abstract presenter:* Valerio Baldelli (Milan, Italy)

WS11.03      **Infectious dynamics of bacteriophages that lyse diverse cystic fibrosis *Stenotrophomonas maltophilia* isolates**      15:30 - 15:45

*Oral abstract presenter:* Cristian Crisan (Atlanta, United States)

WS11.04      **Unraveling the pathogenicity of *mycobacterium abscessus* in cystic fibrosis pulmonary epithelial cell and mouse models of respiratory infection**      15:45 - 16:00

*Oral abstract presenter:* Francesca Nicola (Milan, Italy)

WS11.05      **Spatio-temporal association of *Pseudomonas aeruginosa* and *Staphylococcus aureus* in cystic fibrosis patients**      16:00 - 16:15

*Oral abstract presenter:* Valerie Waters (Toronto, Canada)

WS11.06      **Resistance to the combination of β-lactams and β-lactamase inhibitors in *Mycobacterium abscessus***      16:15 - 16:30

*Oral abstract presenter:* Maria Bitar (Paris, France)*Workshop*

15:00 - 16:30

**WS12 - WS12 - The changing nutrition markers in the age of modulators***Moderator:* Chris Smith (Brighton, United Kingdom)*Moderator:* Carla Colombo (Milano, Italy)

WS12.01      **Final height in cystic fibrosis: what are the predictive factors?**      15:00 - 15:15

*Oral abstract presenter:* Bat El Bar Aluma (Ramat Gan, Israel)

WS12.02      **Dietary protein intake and overall diet quality in adults with cystic fibrosis following elexacaftor/tezacaftor/ivacaftor therapy**      15:15 - 15:30

*Oral abstract presenter:* Laura R. Caley (Leeds, United Kingdom)

WS12.03      **Changes in faecal pancreatic elastase in children with cystic fibrosis after 6 months of elexacaftor/tezacaftor/ivacaftor: results from the BEGIN study**      15:30 - 15:45

Oral abstract presenter: Lucas Hoffman (Seattle, United States)

WS12.04                    **Vitamin levels in children with cystic fibrosis - the effect of elexacaftor/tezacaftor/ivacaftor**                    15:45 - 16:00

Oral abstract presenter: Christine Ronne Hansen (Lund, Sweden)

WS12.05                    **Change in pancreatic status in children aged 2-5 years after initiation of elexacaftor/tezacaftor/ivacaftor**                    16:00 - 16:15

Oral abstract presenter: Phoebe Roper (London, United Kingdom)

WS12.06                    **Exploring the impact of excessive BMI on metabolic health in patients with cystic fibrosis: a 2-year experience with CFTR modulators at the Warsaw CF Centre**                    16:15 - 16:30

Oral abstract presenter: Monika Mielus (Warsaw, Poland)

#### Workshop

15:00 - 16:30

#### **WS13 - WS13 - Updates in genetics screening and diagnosis**

Moderator: Valeria Capurro (Genoa, Italy)

Moderator: Caroline Raynal (Montpellier, France)

WS13.01                    **Characterization of two novel F508del-CFTR complex alleles and their impact on drug responsiveness**                    15:00 - 15:15

Oral abstract presenter: Valeria Tomati (Genoa, Italy)

WS13.02                    **Two children homozygous for the complex allele p.Leu467Phe-p.Phe508del with reduced clinical response to elexacaftor/tezacaftor/ivacaftor but differences in nasal potential difference measurement**                    15:15 - 15:30

Oral abstract presenter: Rebecca Dalferth (Hannover, Germany)

WS13.03                    **The clinical characteristics of CFTR-related disorders (CFTR-RDs): retrospective study from a large national difficult CF diagnosis (DCFD) clinic**                    15:30 - 15:45

Oral abstract presenter: Ladina Weitnauer (London, United Kingdom)

WS13.04                    **Management of intermediate sweat chloride results and diagnosis of CFTR related disorders in a large tertiary paediatric centre**                    15:45 - 16:00

Oral abstract presenter: Katie Rose (Manchester, United Kingdom)

WS13.05                    **Characterization of a frameshift variant by means of patient-derived nasal epithelial cells: molecular and functional analysis of CFTR mRNA and protein**                    16:00 - 16:15

Oral abstract presenter: Cristina Pastorino (Genoa, Italy)

WS13.06                    **Absence of neonatal screening for cystic fibrosis in Sweden causes delay in effective treatment**                    16:15 - 16:30

Oral abstract presenter: Christina Krantz (Uppsala, Sweden)

#### Workshop

15:00 - 16:30

#### **WS14 - WS14 - Therapeutic approaches for CFTR mutations**

Moderator: Nicoletta Pedemonte (Genoa, Italy)

Moderator: Alexandre Hinzpeter (Paris, France)

WS14.01                    **Primary nasal epithelial cells for personalized medicine in non-eligible cystic fibrosis patients**                    15:00 - 15:15

Oral abstract presenter: Jasmin Berger (Berlin, Germany)

WS14.02                    **In silico, in vitro and ex vivo characterization of CFTR pathogenic variants localized in the Fourth Intracellular Loop and their rescue by modulators**                    15:15 - 15:30

Oral abstract presenter: Emanuela Pesce (Genova, Italy)

WS14.03	<b>Novel pharmacological inhibitors of the NMD mechanism to rescue CFTR function in cystic fibrosis patients with nonsense mutations</b>	15:30 - 15:45
<i>Oral abstract presenter:</i> Arianna Venturini (Pozzuoli, Italy)		
WS14.04	<b>Small molecules acting as eRF degraders differently rescue G542X and W1282X-CFTR function</b>	15:45 - 16:00
<i>Oral abstract presenter:</i> Anna Borrelli (Pozzuoli, Italy)		
WS14.05	<b>Effect of vanzacaftor/tezacaftor/ivacaftor on cystic fibrosis airway epithelial cells</b>	16:00 - 16:15
<i>Oral abstract presenter:</i> Tereza Dousova (Praha 5, Czech Republic)		
WS14.06	<b>Novel targets to regulate the abundance of G542X CFTR mRNA</b>	16:15 - 16:30
<i>Oral abstract presenter:</i> Carlos M Farinha (Lisboa, Portugal)		

*ECFS Tomorrow Lounge Session*

15:00 - 16:30

**Shared experiences in cross border collaboration***Moderator:* Helen Chadwick (Leeds, United Kingdom)*Moderator:* Hilde de Keyser (Belgium)*Poster Mounting and Dismounting*

15:30 - 16:30

**Poster Dismounting***ECFS Tomorrow Lounge Session*

16:30 - 17:00

**Speaker Corner***Speaker:* Trudy Havermans (Leuven, Belgium)*Speaker:* Eitan Kerem (Jerusalem, Israel)*Speaker:* Catherine Armbruster (Pittsburgh, United States)*Speaker:* Marco Zampoli (Cape Town, South Africa)*Coffee Break*

16:30 - 17:00

**Coffee Break***Workshop*

17:00 - 18:30

**WS15 - WS15 - ETI era: transforming outcomes from lung function to longevity***Moderator:* Damian Downey (Belfast, United Kingdom)*Moderator:* Silke van Koningsbruggen-Rietschel (Cologne, Germany)

WS15.01	<b>Post-lung transplant survival for people with cystic fibrosis before and during the elexacaftor/tezacaftor/ivacaftor era</b>	17:00 - 17:15
---------	---	---------------

*Oral abstract presenter:* Kathleen J. Ramos (Seattle, United States)

WS15.05	<b>Elexacaftor/tezacaftor/ivacaftor improves bronchial dilatation in a real-world cohort of adolescents with cystic fibrosis</b>	17:15 - 17:30
---------	--	---------------

*Oral abstract presenter:* Isabelle Sermet-Gaudelus (Paris, France)

WS15.02	<b>Impact of one versus two responsive CFTR variants on sweat chloride and FEV<sub>1</sub> responses to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a real-world study</b>	17:30 - 17:45
---------	---	---------------

*Oral abstract presenter:* Pierre-Régis Burgel (Paris, France)

WS15.03	<b>Elevated sweat chloride concentrations in people with cystic fibrosis with at least one N1303K, 2789+5G&amp;GT;A or R334W treated with elexacaftor/tezacaftor/ivacaftor</b>	17:45 - 18:00
---------	--	---------------

*Oral abstract presenter:* Pierre-Régis Burgel (Paris, France)

WS15.04 **elexacaftor/tezacaftor/ivacaftor CFTR modulators mitigates senescence in cystic fibrosis** 18:00 - 18:15

*Oral abstract presenter:* Valentino Bezzerri (Verona, Italy)

WS15.06 **Comparison of the Leeds criteria and CFHealthHub criteria for classification of chronic *Pseudomonas aeruginosa* infection in people with cystic fibrosis in the post-modulator era** 18:15 - 18:30

*Oral abstract presenter:* Gabriella Bonsignore (Sheffield, United Kingdom)

*Workshop*  
17:00 - 18:30

**WS16 - WS16 - Cystic fibrosis related diabetes**

*Moderator:* Dimitri Declercq (Gent, Belgium)

*Moderator:* Charles Haworth (Cambridge, United Kingdom)

WS16.01 **Elucidating the pathogenesis of cystic fibrosis-related diabetes with induced pluripotent stem cells** 17:00 - 17:15

*Oral abstract presenter:* Ishika Khondaker (Houston, United States)

WS16.02 **Cystic fibrosis-related diabetes is associated with islet autoantibody positivity, but not with family history of diabetes in children** 17:15 - 17:30

*Oral abstract presenter:* Boróka Borbála Varga (Pécs, Hungary)

WS16.03 **The prevalence and probability of cystic fibrosis-related diabetes in children under 10: a prospective cohort study** 17:30 - 17:45

*Oral abstract presenter:* Szabolcs Kiss (Budapest, Hungary)

WS16.04 **The effects of cystic fibrosis transmembrane conductance regulator modulator therapy on glycaemic control in patients with cystic fibrosis: a meta-analysis** 17:45 - 18:00

*Oral abstract presenter:* Szabolcs Kiss (Budapest, Hungary)

WS16.05 **Impact of elexacaftor/tezacaftor/ivacaftor on glucose tolerance in adolescents with cystic fibrosis. Data from the MODUL-CF study** 18:00 - 18:15

*Oral abstract presenter:* Isabelle Sermet-Gaudelus (Paris, France)

WS16.06 **Amylase as a potential non-insulin adjunct to manage CF-related blood glucose levels** 18:15 - 18:30

*Oral abstract presenter:* Steven D. Freedman (Boston, United States)

*Workshop*  
17:00 - 18:30

**WS17 - WS17 - Late Breaking Science**

*Moderator:* Isabelle Fajac (Paris, France)

*Moderator:* Batsheva Kerem (Jerusalem, Israel)

**Highlights of the ECFS Basic Science Conference 2025**

17:00 - 17:25

*Speaker:* Batsheva Kerem (Jerusalem, Israel)

**Recording: Precise prime editing and virus-like particle delivery for drug-refractory *CFTR* mutations**

17:25 - 17:45

*Speaker:* Mattijs Bulcaen (Leuven, Belgium)

**The association between sweat chloride and outcomes following treatment with *CFTR* modulators including vanzacaftor/tezacaftor/deutivacaftor**

17:45 - 18:00

*Oral abstract presenter:* Edith Zemanick (Aurora, United States)

**Early biofilm inhibition by N-acetylcysteine and lutein against *Pseudomonas aeruginosa* PAO1: A potential strategy for cystic fibrosis adjunctive therapy**

18:00 - 18:15

*Oral abstract presenter:* Imane Abidli (Belgium)

**Artificial intelligence driven CT comparison between cystic fibrosis**

18:15 - 18:30

**and primary ciliary dyskinesia**

Oral abstract presenter: Stéphanie Bui (Bordeaux, France)

**Workshop**

17:00 - 18:30

**WS18 - WS18 - Complex Psychosocial Issues/Nursing Case studies**

Moderator: Trudy Havermans (Leuven, Belgium)

Moderator: Dorien Holtslag (Maastricht, Netherlands)

WS18.01 **Benefits of advanced care planning to families and healthcare professionals: a case report** 17:00 - 17:18

Oral case presenter: Nicky Surfleet (Birmingham, United Kingdom)

WS18.02 **What do we do when patient goals diverge from the medical team's priorities? A psychological case study** 17:18 - 17:36

Oral case presenter: Daniel Goldstone (Dublin, Ireland)

WS18.03 **A case of improved compliance with pancreatic enzyme replacement therapy in a paediatric patient, resulting in insulin therapy cessation** 17:36 - 17:54

Oral case presenter: Claire Berry (Liverpool, United Kingdom)

WS18.04 **Use of a standardized behavioral health questionnaire to support ETI dose adjustment in a teen with concerns for adverse mental health effects of ETI** 17:54 - 18:12

Oral case presenter: Freda Liu (Seattle, United States)

WS18.05 **Interpersonal Psychotherapy for depression in cystic fibrosis: two case studies** 18:12 - 18:30

Oral case presenter: Catherine O'Leary (Cardiff, United Kingdom)

**Workshop**

17:00 - 18:30

**WS19 - WS19 - Upstream/downstream: new therapies for people with cystic fibrosis**

Moderator: Lieven Dupont (Leuven, Belgium)

Moderator: Helen Barr (Nottingham, United Kingdom)

WS19.01 **Stabilizers of CFTR NBD1 synergize with galicaftor (SION-2222) or SION-109 to enable full correction of  $\Delta F508$ -CFTR** 17:00 - 17:15

Oral abstract presenter: Gregory Hurlbut (Waltham, United States)

WS19.02 **Unlocking cAMP modulation: a new peptide targeting PI3K $\gamma$  in pulmonary cells** 17:15 - 17:30

Oral abstract presenter: Angela Della Sala (Turin, Italy)

WS19.03 **Improvements in structural lung disease over 24 months in children with CF aged 6-11 on elexacaftor/tezacaftor/ivacaftor (ETI) - interim analysis using automated LungQ scoring** 17:30 - 17:45

Oral abstract presenter: Paul McNally (Dublin, Ireland)

WS19.04 **Quality of life with VNZ/TEZ/D-IVA versus ELX/TEZ/IVA in people with cystic fibrosis aged  $\geq 6$  years: post hoc analyses from phase 3 randomized, controlled and open label extension trials** 17:45 - 18:00

Oral abstract presenter: Claire Wainwright (Brisbane, Australia)

WS19.05 **A Phase II trial (CLAIRAFly) to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the dipeptidyl peptidase 1 inhibitor BI 1291583 in adults with bronchiectasis due to cystic fibrosis** 18:00 - 18:15

Oral abstract presenter: Marcus A. Mall (Berlin, Germany)

WS19.06 **Probiotics and the EARly Life effects on intestinal bacteria and inflammation in children with Cystic Fibrosis (PEARL-CF) Study** 18:15 - 18:30

Oral abstract presenter: Michael J Coffey (Sydney, Australia)



*Poster Mounting and Dismounting*  
17:00 - 18:00

**Poster Dismounting**

**Saturday, 07. June 2025***Symposium*

09:00 - 10:30

**S21 - Symposium 21 - Grand Rounds in Clinical CF***Moderator:* Peter Barry (Manchester, United Kingdom)*Moderator:* Amy Downes (London, United Kingdom)**A novel desensitization experience in skin reactions; a rare but difficult to manage complication of modulator therapy**

09:00 - 09:15

*Speaker:* Özge Ülgen (Istanbul, Turkey)*Discussant:* Peter Barry (Manchester, United Kingdom)*Discussant:* Lieven Dupont (Leuven, Belgium)**Absent response to CFTR Modulator in 2 patients compound heterozygous for F508Del and a complex allele**

09:15 - 09:30

*Speaker:* Alanood Alagedi (London, United Kingdom)*Discussant:* Hettie Janssens (Rotterdam, Netherlands)**Life-threatening Lomentospora prolificans infection and bronchomalacia in a child with Cystic Fibrosis (CF) managed with biodegradable endobronchial stenting**

09:30 - 09:45

*Speaker:* Angela Tang (Bristol, United Kingdom)*Discussant:* Ian Balfour-Lynn (London, United Kingdom)**The role of GLP-1 agonists in the management of obesity in Adult people with Cystic Fibrosis (PwCF) in an era of CFTR modulation**

09:45 - 10:00

*Speaker:* Seamus Lehane (Cork, Ireland)*Discussant:* Peter Barry (Manchester, United Kingdom)**Unexplained severe respiratory distress in a neonate with cystic fibrosis: any IgE ideas?**

10:00 - 10:15

*Speaker:* Nadia Audi (London, United Kingdom)*Discussant:* Silvia Gartner (Barcelona, Spain)**A post-transplant puzzle: Unravelling leg pain, hypotension and shock in a person with CF post lung transplant**

10:15 - 10:30

*Speaker:* Mark Ward (Dublin, Ireland)*Discussant:* Lieven Dupont (Leuven, Belgium)*Symposium*

09:00 - 10:30

**S22 - Symposium 22 - Above the glottis***Moderator:* Simone Hadjisymeou Andreou (London, United Kingdom)*Moderator:* Don Sanders (Indianapolis, United States)**Sinonasal infection and inflammation in cystic fibrosis, a united airway**

09:00 - 09:22

*Speaker:* Don Sanders (Indianapolis, United States)**Sinonasal imaging in cystic fibrosis**

09:22 - 09:44

*Speaker:* Lena Wucherpfennig (Heidelberg, Germany)**What is the place for surgery for sinonasal disease in cystic fibrosis?**

09:44 - 10:06

*Speaker:* Daniel Beswick (Los Angeles, United States)**Hearing impairment in cystic fibrosis**

10:06 - 10:30

*Speaker:* Jamie Cheong (London, United Kingdom)

## Symposium

09:00 - 10:30

**S23 - Symposium 23 - Managing metabolic health in cystic fibrosis**

Moderator: Dimitri Declercq (Gent, Belgium)

Moderator: Andrea Párnitzky (Budapest, Hungary)

**Non-insulin therapies in glucose abnormalities in the era of CFTR modulators**

09:00 - 09:22

Speaker: Amir Moheet (Minneapolis, United States)

**Cardiovascular disease in cystic fibrosis - a challenge on the horizon?**

09:22 - 09:44

Speaker: Freddy Frost (Liverpool, United Kingdom)

**How can we modulate and improve microbiota by diet?**

09:44 - 10:06

Speaker: Tamarah Katz (Sydney, Australia)

**Shaping health - physical activity in improving longer and better life**

10:06 - 10:30

Speaker: Wolfgang Gruber (Kiel, Germany)

## Symposium

09:00 - 10:30

**S24 - Symposium 24 - Unlocking the power of registries: enhancing our understanding of cystic fibrosis and futureproofing data collection**

Moderator: Uros Krivec (Ljubljana, Slovenia)

Moderator: Egil Bakkeheim (Oslo, Norway)

**Current and emerging comorbidities and disease trajectories in the CFTR modulator era**

09:00 - 09:22

Speaker: Barry Plant (Cork, Ireland)

**Preparing for tomorrow's challenges: is data collection fit for purpose?**

09:22 - 09:44

Speaker: Gwyneth Davies (London, United Kingdom)

**From numbers to narratives: the importance of patient reported outcomes in registry studies**

09:44 - 10:06

Speaker: Elise Lammertyn (Brussels, Belgium)

**Options and outcomes: eligible but intolerant of variant specific therapy**

10:06 - 10:30

Speaker: Daniel Peckham (Leeds, United Kingdom)

## Symposium

09:00 - 10:30

**S25 - Symposium 25 - Lung disease modelling - learning from other lung diseases**

Moderator: Shafagh Waters (Sydney, Australia)

Moderator: Pascale Fanen (Créteil, France)

**Recording: SMG organoids to study CF pathophysiology**

09:00 - 09:22

Speaker: Brigitte Gomperts (Los Angeles, United States)

**Advanced lung models for studying infection, regeneration**

09:22 - 09:44

Speaker: Anne van der Does (Leiden, Netherlands)

**Human *in vitro* airway models for studying CF, PCD, asthma - phenotypic read-outs and upscaling**

09:44 - 10:06

Speaker: Gimano Amatngalim (Utrecht, Netherlands)

**ABCA3: Another ABC transporter shaping lung function and disease**

10:06 - 10:30

Speaker: Alix de Becdelièvre (CRETEIL, France)

*Coffee Break*

10:30 - 11:00

**Coffee Break**

*Closing Plenary*

11:00 - 12:30

**Closing Plenary**

*Moderator:* Jane Davies (London, United Kingdom)

*Moderator:* Carlo Castellani (Genoa, Italy)

*Moderator:* Francesco Blasi (Milan, Italy)

*Moderator:* Nicoletta Pedemonte (Genoa, Italy)

**Basic Science: fueling personalised medicine for cystic fibrosis**

11:00 - 11:30

*Speaker:* Nicoletta Pedemonte (Genoa, Italy)

**The secret ingredient for optimising growth and development**

11:30 - 12:00

*Speaker:* Chris Smith (Brighton, United Kingdom)

**ECFS President Address**

12:00 - 12:30

*Speaker:* Jane Davies (London, United Kingdom)